COMPOSITION FOR THE DIAGNOSIS, PREVENTION OR TREATMENT OF DISEASES RELATED TO CELLS EXPRESSING IL-8 OR GRO-ALPHA, COMPRISING UCB-MSCs

ABSTRACT

Provided is a gene therapy composition for transferring one of a therapeutical gene, a maker gene, or a mixture thereof to a cell that expresses interleukin-8(IL-8) or GRO-α and induces tropism of mesenchymal stem cells isolated from umbilical cord blood and/or the mesenchymal stem cells expanded from said mesenchymal stem cells (UCB-MSCs), wherein the cell-treating composition includes UCB-MSCs. Provided is a composition for treating disease related to a cell expressing IL-8 or GRO-α, that is, a brain tumor in gene therapy, by using UCB-MSCs. Provided is a composition or kit for diagnosing brain tumors, preventing brain tumors, treating brain tumors, or monitoring brain tumor treatment progression by using UCB-MSCs.

TECHNICAL FIELD

The present invention relates to a gene therapy composition for transferring a therapeutical gene, a marker gene, or a product thereof to a cell that expresses interleukin-8(IL-8) or GRO-α and induces tropism of umbilical cord blood-derived mesenchymal stem cells or mesenchymal stem cells isolated from umbilical cord blood and/or the mesenchymal stem cells expanded from said mesenchymal stem cells (UCB-MSCs), wherein the gene therapy composition includes UCB-MSCs.

The present invention also relates to preventing or treating disease related to a cell expressing IL-8 or GRO-α, or brain tumors in gene therapy, using the composition includes UCB-MSCs.

The present invention also relates to a composition or kit for diagnosing brain tumors, preventing brain tumors, treating brain tumors, or monitoring brain tumor treatment progression, using UCB-MSCs.

BACKGROUND ART

It is known that stem cells migrate toward sites of pathology. Recently, it was found that bone marrow-derived mesenchymal stem cells (BM-MSCs) have a tropism for tumors and migrate toward tumor sites. Such BM-MSCs that can migrate to sites of specific tumors may prove to be a useful tool in gene therapy. For example, BM-MSCs having a tropism for tumors can be used as vehicles for transferring a therapeutic suicide gene to tumor sites [see Ponte A. L. et al., Stem Cells, 25, 1737-1745 (2005); Kahler C. M. et al., Respir Res 8, 50 (2007)]. Despite this interesting phenomenon, the molecular mechanisms regulating MSCs trafficking to tumor are unclear.

Growing evidence over several years indicates that induction of BM-MSCs migration seems to be stimulated by several soluble factors. Recently, monocyte chemoattractant protein-1 (MCP-1) secreted from breast cancer cells has been shown to stimulate BM-MSCs migration [see Dwyer R. M. et al. Clin Cancer Res 13, 5020-5027 (2007)]. Furthermore, chemokine ligand2 (CCL2) and chemokine ligand10 (CCL-10) can induce the migration of neural progenitor cells to sites damaged within the middle

cerebral artery occlusion (MCAo) stroke model [see J Neurosci Res 85, 2120-2125 (2007)]. An insulin-like growth factor-1 (IGF-1) markedly increased the rat BM-MSCs migratory response [see Li Y. et al. Biochem Biophys Res Commun 356, 780-784 (2007)]. Therefore, identifying the soluble factors that affect migration events of MSCs is important for understanding-how MSCs migrate toward tumors or damaged tissues.

Genes introduced to BM-MSCs are over-expressed in vivo and show bioactivity. For example, BM-MSCs to which a human hAng1 gene is introduced stimulate generation of blood to vessels in an infarction site of an acute myocardial infarction model animal [see Sun L. et al., Biochemical Biophysical Research Communication 357 (2007) 779-784], BM-MSCs overexpressing Akt surprisingly treat myocardial infarction and improve functions of heart [see Nicolas N. et al., Molecular Therapy 14(6), 840-850, 2006], Bcl-2 gene-modified BM-MSCs prevent apoptosis and improve functions of heart [see Stem Cells 25, 2118-2127 (2007)], and BM-MSCs overexpressing endothelial nitric oxide synthase recovers the damage of right ventricular caused by pulmonary hypertension [see Sachiko et al., Circulation, 114[suppl I]:I-181˜I-185]. These results indicate that MSCs to which genes are introduced can be used as a tool in gene therapy.

Meanwhile, in general, cells of the central nervous system are well regulated, wherein the central nervous system consists of a brain and a spinal cord. However, when this regulation collapses, cells are continuously divided and tumors are formed. Tumors can be categorized as benign tumors or malignant tumors. The central nervous system has neurons, and glia cells that support and protect the neurons. Tumors generated in glia cells are known as glioma. Glioma accounts for 50% of primary brain tumors and accounts for 15% of primary spinal cord tumors. In addition, brain tumors include neural tumors, blood vessel tumors, and gland tumors. There is also a secondary brain tumor caused by other tumors developed in other sites of the body. The secondary brain tumor is the most common type of brain tumor.

Treating brain tumors are difficult due to the sites of the tumors. Brain tumors can be treated by physical surgery or chemotherapy. For physical surgery, when tumor sites are completely removed, complications are likely to occur. For chemotherapy, a high-concentration anticancer drug needs to be injected due to a brain-blood barrier, and thus, it seriously damages other organs. Recently, gene therapy has been used to treat brain tumors. In gene therapy, a gene is introduced for suppressing growth of cancer cells by using a virus vector. Since the virus vector does not have a selective migration capability toward a target cancer site, the virus vector is surface-modified to obtain such capability. However, there is a limit to migrate a sufficient amount of virus vectors to the target cancer site.

Research results on a homing effect, which is a phenomenon in which stem cells migrate toward a disease site, have been disclosed, indicating that stem cells can be useful delivery media for treating brain tumors. However, mechanisms regulating stem cells trafficking to tumors are unclear. It is known that neural stem cells have a tropism for a type of brain tumor, that is, malignant glioma. Based on this theory, research into a method of transferring genes to a brain tumor site by using neural stem cells that function as a vehicle is being conducted (see Yip S et al., The Cancer J 9(3), 189-204, 2003; Kim S K et al., Clin Cancer Res 12(18), 5550-5556, 2006). Yip et al. found that brain tumors can be treated with neural stem cells carrying an immune regulatory gene, an apoptosis promoting gene, a pro-drug converting enzyme, an oncolytic virus, etc. Brown et al. identified that brain tumors can be effectively treated by injecting a cytosine deaminase gene-containing vector into the brain, wherein the cytosine deaminase gene changes 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU), wherein 5-FU is an anticancer drug and 5-FC is a prodrug of 5-FU (see Brown A B et al., Human Gene Ther. 14(18), 1777-1785, 2003). Ehtesham et al. reported that growth of brain tumors was decreased by injecting neural stem cells treated for delivering interleukin-12 or a tumor necrosis factor-related apoptosis-inducing ligand (Cancer Res 62, 5657-5663, 2002; Cancer Res 62, 7170-7174, 2002). However, using neural stem cell in clinical experiments causes ethical problems related to how neural stem cells are taken, and immunological rejection caused by allogenic transplantation. Accordingly, there is a need to find other types of stem cells that do not cause these problems and can be easily obtained.

Akira et al. disclosed that BM-MSCs have a tropism for brain tumors (see Cancer Res 65(8), 3307-3316, 2005). BM-MSCs can be taken from patients. When BM-MSCs are injected through autologous transplantation, immunological rejection does not occur, which is an advantage for a clinical use. In a study, human BM-MSCs were injected into nude mice having skulls transplanted with human glioma cell lines through a carotid artery. As a result, the human BM-MSCs were found only in glioma and not in a normal part of the brain adjacent to glioma. In addition, even when human BM-MSCs were transplanted into a skull, human BM-MSCs migrated toward glioma. When human BM-MSCs were infected with an adenovirus vector containing cDNA of an IFN-beta gene and then the resultant vector was injected into a glioma-transplanted skull of a nude mouse through a carotid artery, the lifetime of the nude mouse was increased. WO07/037,653A1 discloses a composition for treating cancer, comprising BM-MSCs expressing a cytosine deaminase gene. In this case, however, since BM-MSCs are taken through a plurality of complex processes, subjects from which the BM-MSCs are taken suffer from mental and physical stress for a long period of time. Accordingly, there is a need to find other types of stem cells.

Unlike bone marrow, umbilical cord blood (UCB) having many MSCs can be easily taken from umbilical cords which were discarded in delivery processes. Also, the UCB storage industry is well established and thus, it is easy to find donors. Even when MSCs taken from other human-induced UCB are used, immunological rejection does not occur after transplantation. Accordingly, high immunological stability can be obtained. Therefore, it is very important to identify whether a disease such as a brain tumor can be treated based on tropisom of UCB MSCs. However, such attempts for identifying availability of UCB-MSCs have not yet been made. All the references cited in the present specification are incorporated by reference in their entity. Also, all the information disclosed in the present specification is used only to help understanding of the background of the present inventive concept and cannot be prior art.

DETAILED DESCRIPTION OF THE INVENTION Technical Problem

Target gene therapy recently developed uses specific migration characteristics of mesenchymal stem cells (MSCs), in which therapeutical genes are introduced to MSCs and then the resultant MSCs are migrated to a disease site and the disease is treated. To develop gene therapy using tropism of MSCs, a molecular mechanism regulating the migration of MSCs toward disease site, for example tumors should be completely understood. However, the molecular mechanism has not yet been determined. Accordingly, the present inventive concept is to find out the molecular mechanism of UCB-MSCs migrating toward a disease site cell, for example, tumor cell and uses the molecular mechanism in gene therapy.

Although research into whether a disease condition, for example, tumor, including brain tumors can be treated with neural stem cells or bone marrow-derived mesenchymal stem cells (BM-MSCs) are being conducted, collecting neural stem cells and BM-MSCs may lead to ethical problems, immunological rejection, and mental and physical stress of a subject from which BM-MSCs are taken. Accordingly, the present inventive concept also provides a stem cell that can be taken without these problems described above and have better tropism for disease site for example, tumors such as brain tumors.

Technical Solution

The inventors of the present invention have conducted research in order to solve these problems, and found that mesenchymal stem cells isolated from umbilical cord blood and/or the mesenchymal stem cells expanded from said mesenchymal stem cells (UCB-MSCs) have a tropism for a cell expressing at least one selected from the group consisting of IL-8 and GRO-α, for example a tumor cell such as brain tumor cells and that UCB-MSCs have a stronger migration capability than mesenchymal stem cells isolated from bone marrow and/or the mesenchymal stem cells expanded from said mesenchymal stem cells (BM-MSCs). The inventors have provided a therapeutical application for treating a disease condition, for example a tumor cell such as brain tumor using UCB-MSCs.

Also, the inventors of the present invention found the tropism of UCB-MSCs is affected by interleukin-8 (IL-8) or GRO-α. Based on this finding, the inventors of the present invention provide a method of delivering a therapeutical gene or a product thereof to a cell that expresses IL-8 or GRO-α and induces the tropism of UCB-MSCs, and a therapeutical application thereof.

Advantageous Effects

Umbilical cord blood derived mesenchymal stem cells (UCB-MSCs) in the composition according to the present invention has a selective tropism for cells that express IL-8 or GRO-α and thus induce the tropism of UCB-MSCs or brain tumor cells. The tropism capability of the UCB-MSCs is better than that of other stem cells and thus, therapeutical genes or a product thereof can be more effectively delivered than when other conventional stem cells are used. Accordingly, a pharmaceutical composition or a kit comprising UCB-MSCs according to the present invention can be used to diagnose, prevent, and treat diseases related to cells expressing interleukin (IL)-8 or GRO-α or brain tumors.

MODE OF INVENTIONS

The inventors of the present invention have studied stem cells having an effective tropism for tumors, and surprisingly found that umbilical cord blood-derived mesenchymal stem cells (UCB-MSCs) have a strong tropism for brain tumors, specifically a stronger tropism for brain tumors than bone marrow-derived mesenchymal stem cells (BM-MSCs), which has never been known before. Also, the inventors found that at least one selected from the group consisting of interleukin (IL)-8 and GRO-α relates to the tropism of UCB-MSCs.

The inventors co-cultured UCB-MSCs and representative tumor cell lines to identify characteristics of the tropism of UCB-MSCs and cytokine related to those tumor cell lines. Specifically, UCB-MSCs, and one selected from human brain tumor cell lines, such as U-87 MG, LN18, U138, or U251 cells; human rectal cancer cell line such as LS-174T; human B lymphocyte such as NC37; mouse's fibroblast (NIH3T3); a gastric cancer cell line such as KATO III; a lung cancer cell line such as A549, and a liver cancer cell line such as PLC/PRF5 were co-cultured in a transwell chamber to measure mobility of UCB-MSCs. As a result, it was found that UCB-MSCs have a strong tropism for U-87 MG, LN18, U138, and U251 cells which are brain tumor cells (see FIGS. 3 and 4). UCB-MSCs also had tropism for a conditioned media that did not include U-87 MG cells and was obtained by culturing U-87 MG (see FIG. 4).

Also, the tropism for a brain tumor cell line of UCB-MSCs was compared with that of BM-MSCs that is currently used as a source of stem cells. As a result, it was found that UCB-MSCs have a stronger tropism for a brain tumor cell line than BM-MSCs (FIG. 5). Also, the chemotactic index of UCB-MSCs was largest with respect to the brain tumor cell line among various cancer cell lines (FIG. 6). Such a high chemotactic index with respect to the brain tumor cell is an additional advantage of UCB-MSCs, in addition to the fact that UCB-MSCs can be obtained more easily and have more immunological stability than BM-MSCs, proving that UCB-MSCs are a very suitable medium for gene therapy of a brain tumor because a therapeutical gene can be efficiently transferred to the inside or neighboring portions of the brain tumor.

The tropism of UCB-MSCs in the transwell chamber may be derived by cytokines that are derived to be secreted in the co-culture of two cells. Thus, two cells were co-cultured in a transwell chamber to prepare a medium and then, the medium was analyzed using the cytokine array. As a result, it was identified that high levels of cytokines, such as IL-8 or GRO-α, were secreted in a medium in which UCB-MSCs and U87 MG had been co-cultured (see FIG. 7). Accordingly, it is highly likely that these cytokines may derive a tropism of the UCB-MSCs.

The inventors of the present invention cultured UCB-MSCs alone, cultured U-87 MG alone, and co-cultured UCB-MSCs and U-87 MG, and then analyzed IL-8 mRNA levels of these cells using RT-PCR. As a result, UCB-MSCs did not express IL-8 in either the presence or absence of U-87 MG cells. However, U-87 MG expressed IL-8 constitutively in both the presence and absence of UCB-MSCs (see FIG. 8). Treatment of UCB-MSCs with IL-8 significantly enhanced its migration when compared to untreated cells (see (A) of FIG. 9). However, when UCB-MSCs were pre-incubated with anti-CXCR1 antibodies that are antibodies with respect to an IL-8 receptor and recombinant IL-8 was applied to UCB-MSCs, IL-8 mediated migration of UCB-MSCs were reduced in a dose-dependent manner by anti-CXCR1 treatment ((B) of FIG. 9). Anti-CXCR2 treatment also showed the same effect. Similarly, GRO-α treatment also enhanced UCB-MSCs migration when compared to untreated UCB-MSCs ((C) of FIG. 9). In contrast, there were no significant differences in UCB-MSCs migration in cultures treated with MCP-1 ((D) of FIG. 9). This data indicates that IL-8 and GRO-α participate in UCB-MSCs migration toward U-87 MG cells.

The co-relationship between the concentration of IL-8 secreted by each cancer cell and UCB-MSCs migration was measured. As a result, U-87 MG, which migrated the highest concentration of UCB-MSCs, showed the highest IL-8 production (FIG. 10A). The inventor also measured IL-8 secretion level in various glioma cells. All tested glioma cell lines which were target cells of UCB-MSC tropism also showed high secretion level of IL-8 ((B) of FIG. 10). This data suggested that UCB-MSCs had a strong migration attraction toward IL-8 secreting cells. In order to identify this, IL-8 was artificially overexpressed in A549 that is a low level of IL-8 expressing human lung cancer cells and then, A549 overexpressing IL-8 and UCB-MSCs were co-cultured. As a result, it was found that although the UCB-MSCs had a poor migration attraction toward A549, UCB-MSCs had a strong migration attraction toward A549 overexpressing IL-8. Therefore, IL-8 could be a strong inducer of UCB-MSCs (see FIG. 10C).

The inventors of the present invention compared migration characteristics of BM-MSCs and UCB-MSCs with respect to U-87 MG cells or IL-8. As a result, it was found that UCB-MSCs migrate more strongly toward U-87 MG cells or IL-8 than BM-MSCs. UCB-MSCs migration is enhanced dramatically in response to IL-8 treatment, but BM-MSCs migration is weak in response to IL-8 treatment (see FIG. 11).

Expression levels of CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2) in UCB-MSCs and BM-MSCs were compared by measuring mRNA and protein (see FIG. 12). RT-PCR analysis using total RNA isolated from UCB-MSCs and BM-MSCs reveal that the PCR product of both CXCR1 and CXCR2 has a higher intensity in UCB-MSCs when compared to BM-MSCs. In regard of protein expression of CXCR1 and CXCR2, CXCR1 and CXCR2 are highly expressed both in UCB-MSCs and BM-MSCs. Since IL-8 has a high affinity to CXCR1 and CXCR2, increased UCB-MSCs migration toward U-87 MG may be due to up-regulated expression of CXCR1 and CXCR2.

The inventors of the present invention performed an experiment of introducing a gene coding green fluorescent protein (GFP) into UCB-MSCs. As a result, it was found that GFP was successfully introduced and expressed (see FIG. 13). Also, it was found that UCB-MSCs overexpressing the gene coding GFP also have a tropism for U87 MG (see FIG. 14). Such results show that UCB-MSCs to which a gene or a product thereof is introduced can be transferred to cells secreting IL-8 or GRO-α.

Based on the results described above, the present invention relates to a method of transferring a gene or product thereof to a cell expressing IL-8 or GRO-α by using UCB-MSCs. The present invention also relates to UCB-MSCs containing a therapeutical composition for transferring a therapeutical or marker gene or a product thereof to a cell that expresses IL-8 or GRO-α and drives tropism of UCB-MSCs. The present invention also relates to a therapeutical pharmaceutical composition, a kit, a use for preventing or treating brain tumors, and a treatment method of brain tumors, using UCB-MSCs. The present invention also relates to a composition, a kit for diagnosing brain tumors or monitoring the progression of brain tumor treatment and a diagnosing method of brain tumor or monitoring method of the progression of brain tumor treatment, using UCB-MSCs.

Specifically, the present inventive concept relates to:

[1] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC;

[2] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein the UCB-MSC functions as a carrier for gene therapy for brain tumors;

[3] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein an anti-tumor gene is introduced to the UCB-MSC;

[4] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein an anti-tumor gene is introduced to the UCB-MSC, wherein the anti-tumor gene is selected from a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory gene, and an angiogenesis inhibitor gene;

[5] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein an anti-tumor gene is introduced to the UCB-MSC, wherein the anti-tumor gene is selected from a tumor suppressor gene, an apoptosis inducing factor gene, a cell cycle regulatory gene, and an angiogenesis inhibitor gene, wherein the tumor suppressor gene may be selected from the group consisting of a gene of phosphatase and tensin homolog (PTEN), a gene of Maspin, a gene of RUNX3, a gene of Caveolin-1, a gene of nm23, a gene of Rb protein, a gene of Brush-1, a gene of inhibitor of tumor growth (ING-4), a gene of survivin, a gene of X chromosome linked inhibitor apoptosis protein (XIAP), a gene of neural apoptosis inhibitory protein (NAIP), and genes of proteins regulating these genes;

[6] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein an anti-tumor gene is introduced to the UCB-MSC, wherein the anti-tumor gene is selected from a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory gene, and an angiogenesis inhibitor gene, wherein the apoptosis-inducing factor gene may be selected from the group consisting of a gene of cytokine, a gene of interleukin, a gene of a tumor necrosis factor (TNF), a gene of interferon (INF-α, INF-β, INF-γ), a gene of a colony stimulating factor (CSFs), a gene of p53, a gene of Apaf-1, a gene of TRAIL, a gene of Caspase, a gene of Bax, a gene of Bad, a gene of FADD, a gene of JNK, a gene of p38 kinase, and genes of proteins regulating these genes;

[7] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein an anti-tumor gene is introduced to the UCB-MSC, wherein the anti-tumor gene is selected from a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory gene, and an angiogenesis inhibitor gene, wherein the cell cycle regulatory gene may be selected from the group consisting of a gene of cdc2, a gene of Cyclin (Cyclin A, Cyclin D, Cyclin E), a gene of cdc25C, a gene of WAF, a gene of INK4, a gene of CDK (CDK1, CDK2, CDK4, CDK6), a gene of Rb protein, a gene of E2F, an antisense or SiRNA thereof, and genes of proteins regulating these genes;

[8] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein an anti-tumor gene is introduced to the UCB-MSC, wherein the anti-tumor gene is selected from a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory gene, and an angiogenesis inhibitor gene, wherein the angiogenesis inhibitor gene may be selected from the group consisting of a gene of thrombospondin-1, a gene of endostatin, a gene of tumstatin, a gene of canstatin, a gene of vastatin, a gene of restin, a gene of a vascular endothelial growth inhibitor, a gene of maspin, a gene of angiopoietins, a gene of 16-kd prolactin fragment, and a gene of endorepellin;

[9] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein a prodrug converting enzyme gene is introduced to the UCB-MSC;

[10] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein a prodrug converting enzyme gene is introduced to the UCB-MSC, wherein the prodrug converting enzyme gene is selected from cytosine deaminase and CYP2B1 gene;

[11] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein an antisense or SiRNA of a gene related to a brain tumor is introduced to the UCB-MSC;

[12] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein an antisense or SiRNA of a gene related to a brain tumor is introduced to the UCB-MSC, wherein the gene related to a brain tumor may be selected from the group consisting of a gene of Ras family, a gene of c-myc, a gene of abl, a gene of erbB-1, a gene of EGF-R, a gene of Bax, a gene of Apaf-1 interacting protein (APIP), a gene of Wnt-1-induced secreted protein 1 (WISP-1), a gene of Wnt, a gene of Raf-1, a gene of Src, a gene of Akt, a gene of Erk-1,2 and a gene of BcL-2;

[13] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein an oncolytic virus is introduced to the UCB-MSC;

[14] a pharmaceutical composition for preventing or treating brain tumors, wherein the pharmaceutical composition comprises a UCB-MSC, wherein an oncolytic virus is introduced to the UCB-MSC, wherein the oncolytic virus is selected from Herpes simplex virus and Reovirus type 3;

[15] any one of the pharmaceutical compositions for preventing or treating brain tumors described above, wherein the brain tumor is selected from the group consisting of Astrocytoma, Pilocytic astrocytoma, Low-grade Astrocytoma, Anaplastic Astrocytoma, Glioblastoma Multiforme, Brain Stem Glioma, Ependymoma, Subependymoma, Ganglioneuroma, Mixed Glioma, Oligodendroglioma, Optic Nerve Glioma, Acoustic Neuroma, Chordoma, CNS Lymphoma, Craniopharyngioma, Hemangioblastoma, Medulloblastoma, Meningioma, Pineal Tumors, Pituitary Tumors, Primitive Neuroectodermal Tumors, Rhabdoid Tumors, Schwannoma, Cysts, Neurofibromatosis, Pseudotumor Cerebri and Tuberous Sclerosis;

[16] a composition for diagnosing brain tumors or monitoring brain tumor treatment progression, wherein the composition includes a UCB-MSC;

[17] a composition for diagnosing brain tumors or monitoring brain tumor treatment progression, wherein the composition includes a UCB-MSC, wherein the UCB-MSC is labeled with a detectable marker;

[18] a composition for diagnosing brain tumors or monitoring brain tumor treatment progression, wherein the composition includes a UCB-MSC, wherein the UCB-MSC is labeled to with a detectable marker, wherein the detectable marker is selected from luciferase-containing enzyme-based fluorescent detector and Tat peptide-derivatized magnetic nanoparticles;

[19] any one of the compositions for diagnosing brain tumors or monitoring brain tumor treatment progression, wherein the brain tumor is selected from the group consisting of Astrocytoma, Pilocytic astrocytoma, Low-grade Astrocytoma, Anaplastic Astrocytoma, Glioblastoma Multiforme, Brain Stem Glioma, Ependymoma, Subependymoma, Ganglioneuroma, Mixed Glioma, Oligodendroglioma, Optic Nerve Glioma, Acoustic Neuroma, Chordoma, CNS Lymphoma, Craniopharyngioma, Hemangioblastoma, Medulloblastoma, Meningioma, Pineal Tumors, Pituitary Tumors, Primitive Neuroectodermal Tumors, Rhabdoid Tumors, Schwannoma, Cysts, Neurofibromatosis, Pseudotumor Cerebri, and Tuberous Sclerosis;

[20] a kit for treating brain tumors, including: an expression vector having a prodrug converting enzyme gene; an UCB-MSC; and an prodrug of anticancer drug;

[21] a kit for treating brain tumors, including: an expression vector having a prodrug converting enzyme gene; an UCB-MSC; and an prodrug of anticancer drug, wherein the prodrug converting enzyme gene is selected from a cytosine deaminase gene and a CYP2B1 gene;

[22] a kit for treating brain tumors, including: an expression vector having a prodrug converting enzyme gene; an UCB-MSC; and an prodrug of anticancer drug, wherein the prodrug converting enzyme gene is selected from a cytosine deaminase gene and a CYP2B1 gene, wherein the UCB-MSC is transfected with the expression vector having a prodrug converting enzyme gene;

[23] any one of the kits described above, wherein the brain tumor is selected from the group consisting of Astrocytoma, Pilocytic astrocytoma, Low-grade Astrocytoma, Anaplastic Astrocytoma, Glioblastoma Multiforme, Brain Stem Glioma, Ependymoma, Subependymoma, Ganglioneuroma, Mixed Glioma, Oligodendroglioma, Optic Nerve Glioma, Acoustic Neuroma, Chordoma, CNS Lymphoma, Craniopharyngioma, Hemangioblastoma, Medulloblastoma, Meningioma, Pineal Tumors, Pituitary Tumors, Primitive Neuroectodermal Tumors, Rhabdoid Tumors, Schwannoma, Cysts, Neurofibromatosis, Pseudotumor Cerebri and Tuberous Sclerosis;

[24] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces tropism of the UCB-MSC;

[25] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces tropism of the UCB-MSC, wherein the UCB-MSC function as a to carrier for gene therapy;

[26] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces tropism of the UCB-MSC, wherein an anti-tumor gene is introduced to the UCB-MSC;

[27] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC, wherein an anti-tumor gene is introduced to the UCB-MSC, wherein the anti-tumor gene is selected from the group consisting of a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory gene, and an angiogenesis inhibitor gene;

[28] a gene-treating composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC, wherein an anti-tumor gene is introduced to the UCB-MSC, wherein the anti-tumor gene is selected from the group consisting of a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory gene, and an angiogenesis inhibitor gene, wherein the tumor suppressor gene may be selected from the group consisting of a gene of phosphatase and tensin homolog (PTEN), a gene of Maspin, a gene of RUNX3, a gene of Caveolin-1, a gene of nm23, a gene of Rb protein, a gene of Brush-1, a gene of inhibitor of tumor growth (ING-4), a gene of survivin, a gene of X chromosome linked inhibitor apoptosis protein (XIAP), a gene of neural apoptosis inhibitory protein (NAIP), and genes of proteins regulating these genes;

[29] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC, wherein an anti-tumor gene is introduced to the UCB-MSC, wherein the anti-tumor gene is selected from the group consisting of a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory gene, and an angiogenesis inhibitor gene, wherein the apoptosis-inducing factor gene may be selected from the group consisting of a gene of cytokine, a gene of interleukin, a gene of a tumor necrosis factor (TNF), a gene of interferon (INF-α, INF-β, INF-γ), a gene of a colony stimulating factor (CSFs), a gene of p53, a gene of Apaf-1, a gene of TRAIL, a gene of Caspase, a gene of Bax, a gene of Bad, a gene of FADD, a gene of JNK, a gene of p38 kinase, and genes of proteins regulating these genes;

[30] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces tropism of the UCB-MSC, wherein an anti-tumor gene is introduced to the UCB-MSC, wherein the anti-tumor gene is selected from the group consisting of a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory gene, and an antiogenesis inhibitor gene, wherein the cell cycle regulatory gene may be selected from the group consisting of a gene of cdc2, a gene of Cyclin (Cyclin A, Cyclin D, Cyclin E), a gene of cdc25C, a gene of WAF, a gene of INK4, a gene of CDK (CDK1, CDK2, CDK4, CDK6), a gene of Rb protein, a gene of E2F, an antisense or SiRNA thereof, and genes of proteins regulating these genes;

[31] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC, wherein an anti-tumor gene is introduced to the UCB-MSC, wherein the anti-tumor gene is selected from the group consisting of a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory gene, and an antiogenesis inhibitor gene, wherein the angiogenesis inhibitor gene may be selected from the group consisting of a gene of thrombospondin-1, a gene of endostatin, a gene of tumstatin, a gene of canstatin, a gene of vastatin, a gene of restin, a gene of a vascular endothelial growth inhibitor, a gene of maspin, a gene of angiopoietins, a gene of 16-kd prolactin fragment, and a gene of endorepellin;

[32] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC, wherein a prodrug converting enzyme gene is introduced to the UCB-MSC;

[33] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC, wherein a prodrug converting enzyme gene is introduced to the UCB-MSC, wherein the prodrug converting enzyme gene is selected from the group consisting of cytosine deaminase gene and a CYP2B1 gene;

[34] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC, wherein an antisense or SiRNA of a gene related to a tumor is introduced to the UCB-MSC;

[35] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC, wherein an antisense or SiRNA of a gene related to a tumor is introduced to the UCB-MSC, wherein the gene related to a tumor may be selected from the group consisting of a gene of Ras family, a gene of c-myc, a gene of abl, a gene of erbB-1, a gene of EGF-R, a gene of Bax, a gene of an Apaf-1 interacting protein (APIP), a gene of Wnt-1-induced secreted protein 1 (WISP-1), a gene of Wnt, a gene of Raf-1, a gene of Src, a gene of Akt, a gene of Erk-1,2 and a gene of BcL-2;

[36] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene-treating composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC, wherein an oncolytic virus is introduced to the UCB-MSC;

[37] a gene therapy composition for transferring a therapeutical gene or product thereof to a cell, wherein the gene therapy composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC, wherein a oncolytic virus is introduced to the UCB-MSC, wherein the oncolytic virus is selected from the group consisting of Herpes simplex virus and Reovirus type 3;

[38] a composition for diagnosing a disease occurring in a site including a cell or monitoring treatment progression of the disease, wherein the composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC;

[39] a composition for diagnosing a disease occurring in a site including a cell or monitoring treatment progression of the disease, wherein the composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC, wherein the UCB-MSC is labeled with a detectable marker; and

[40] a composition for diagnosing a disease occurring in a site including a cell or monitoring treatment progression of the disease, wherein the composition includes a UCB-MSC, wherein the cell expresses IL-8 or GRO-α and induces a tropism of the UCB-MSC, wherein the UCB-MSC is labeled with a detectable marker, wherein the detectable marker may be selected from the group consisting of a luciferase-containing enzyme based fluorescent detector and Tat peptide-derivatized magnetic nanoparticles.

An aspect of the present invention provides a method of preventing or treating a tumor comprising administering to a subject an effective dose of a composition comprising mesenchymal stem cells derived from umbilical cord blood (UCB-MSC).

In the method, the administration may be made by using any known method in the art. The administration may be made for example, by a parenteral administration. The parenteral administration includes an injection. The injection may be made intravascullary, intramuscularly, subcutaneously, intradermally, or intrathecally. the administration may be made systemically or locally. The local administration may include direct administration to the tumor tissue. The composition may be administered into the subject alone or in combination with any anti-cancer drug or prodrug known in the art.

Since UCB-MSCs do not express HLA-DR (Major Histocompatibility Complex class II) that is a major cause for immunological rejection when a tissue or organ is transplanted (see Le Blanc, K C, Exp Hematol, 31:890-896, 2003; and Tse W T et al., Transplantation, 75:389-397, 2003), immunological reactions, such as rejection, which are major problems of transplantation do not occur or can be minimized. Accordingly, UCB-MSCs included in the pharmaceutical composition or used in the method according to the present invention can be taken from, in addition to a self-derived UCB, another subject-derived UCB. According to the present invention, UCB-MSCs can be used after being cryopreserved.

The UCB-MSCs-containing pharmaceutical composition for gene therapy or for preventing or treating diseases according to the present invention may further include pharmaceutically acceptable additives, in addition to the effective component. The UCB-MSCs-containing pharmaceutical composition may be formed into a suitable formulation that can be administered to a body. The suitable formulation may be a non-oral administration formulation, such as an injectable formulation or a locally administrable formulation. For example, a sterilized solution or suspension that includes water or a pharmaceutically acceptable solvent can be non-orally administered in an injectable form. Specifically, water or the pharmaceutically acceptable solvent is appropriately combined with a pharmaceutically acceptable carrier or medium, thereby forming an injectable formulation in a conventionally acceptable unit dosage. Examples of the pharmaceutically acceptable carrier or medium may include sterile water, saline, vegetable oils, emulsifier, suspension, surfactant, stabilizer, excipient, vehicle, an antiseptic substance, a binder, etc.

The injectable formulation described above can be non-orally administered, specifically directly administered to a site of disease, by using a conventional method. Alternatively, the injectable formulation described above can be administered through a cerebrospinal fluid, a vein, or an artery supplying blood to the site of disease, preferably directly administered to neighboring portions of the site of disease in the brain or the spinal cord or the opposite portions thereto. For example, the injectable formulation described can be administered using a clinical method developed by Douglas Kondziolka in Pittsburgh in 1998. That is, a skull of a subject to be administered is cut to a diameter of about 1 cm, the size of a pea, and then a MSC solution mixed with a Hank's balanced salt solution (HBSS) is injected thereto. In this regard, the injecting the MSC solution is performed using an injector including a long needle and a stereotactic frame for accurately injecting the MSC solution into the brain.

The daily dose of UCB-MSCs may be 1×10⁴ to 1×10⁷ cells/kg body weight, preferably 5×10⁵ to 5×10⁶ cells/kg body weight. The daily dose may be administered at once or be divided for several treatments. However, according to the present invention, the administration dose of UCB-MSCs may vary according to the kinds of diseases to be treated, the severity of disease to be treated, administration routes, and the weight, age, and gender of a patient. Accordingly, the administration dose described above does not limit the scope of the present invention.

In the method, the UCB-MSC may be obtained by any known method in the art. For example, to isolate a monocyte including a MSC from an UCB, any known method such as the method disclosed in Korean Registered Patent No. 489248 filed by the applicant of the present application and registered can be used. For example, the isolating method may be a ficoll-Hypaque density gradient method, but is not limited thereto. Specifically, UCB taken from an umbilical vein after delivery and before the placenta is separated is centrifuged with a ficoll-hypaque gradient to obtain a monocyte, and then the monocyte is washed several times to remove impurities therefrom. The resultant monocyte can be directly used for isolation or culture of MSCs, or cryo preserved for a long period of time.

A MSC can be isolated from UCB and cultured using any known method (see Pittinger M F et al. Science, 284: 143-7, 1999; and Lazarus H M et al. Bone Marrow Transplant, 16: 557-64, 1995), such as a method disclosed in Korean Publicated Patent No. 2003-0069115.

First, the isolated UCB may be centrifuged with, for example, a ficoll-Hypaque gradient to separate monocytes including a hematopoietic cell and a MSC, and then, the monocyte may be washed several times to remove impurities therefrom. Then, monocytes may be seeded in an appropriate concentration in a culture dish to grow cells in a form of a single layer. These cells may be identified with a phase-contrast microscope. In the phase-contrast microscopic image, colonies of cells having a homogeneous spindle shape are MSCs. Then, when cells are cultured and grow, cells are sub-cultured and then multiplied until the number of the cells reaches a desired number.

The UCB-MSCs included in the composition or used in the method according to the present invention can be cryopreserved using known methods (see Campos et al., Cryobiology 35:921-924, 1995). A medium for the cryoporeserving process may include 10˜20% fetal bovine serum (FBS) and 10% dimethylsulfoxide (DMSO). The cells may be suspended in the medium until the concentration of cells is about 1×10⁶ to 5×10⁶ cells per 1 mL of medium.

The cell suspension may be divided and each part may be loaded onto a glass or plastic ample for cryopreservation, and then, the sample may be sealed and loaded into a temperature-controlled programmed freezer. Cells may be frozen using a freezing program providing a temperature change of −1° C./minute so that damage to cells can be reduced when frozen cells are thawed. When the temperature of the sample reaches −90° C. or lower, the sample is moved to a liquid nitrogen storage tank having a temperature of −150° C. or lower.

When the frozen cells are thawed, the sample is quickly moved from the liquid nitrogen storage tank to a water bath having a controlled temperature of 37° C. The thawed content in the ample is immediately moved to a culture dish containing a culture medium in a stabilized condition.

A culture medium for isolating and culturing a MSC may be a cell culture medium containing 10% to 30% of FBS. The cell culture medium may be any cell culture medium that is conventionally used in the art. Examples of the cell culture medium may include a medium selected from the group consisting of a DMEM medium, an MEM medium, a α-MEM medium, a McCoys 5A medium, an eagle's basal medium, a CMRL medium, a Glasgow minimum necessarily medium, a (Ham's) F-12 medium, an iscove's modified Dulbecco's medium (IMDM), a (Liebovitz') L-15 medium, a RPMI 1640 medium and a combination thereof. For example, the cell culture medium may be the DMEM medium. During culturing, cells may be suspended so that the concentration of cells is about 5×10³ to 2×10⁴ cells per 1 mL of the medium.

Also, the cell culture medium may further include one or more additives, if required. The additives may include at least one material selected from the group consisting of: a serum of fetal calf, horse or human; a penicillin G for preventing microorganism contamination; antibiotics such as streptomycin sulfate or gentamycin; antifungal agents such as amphotericin B or nystatin; and mixtures of at least two materials selected from the forgoing.

In the method, the UCB-MSCs may be genetically engineered so as to transfer a therapeutic drug for substantially inhibiting growth of brain tumor cells. Also, the UCB-MSCs may be genetically engineered so as to transfer a therapeutical gene or product thereof to cells secreting IL-8 or GRO-α. In this regard, the term “inhibiting” refers to inhibiting cell is proliferation and growth, in addition necrosis and apoptosis. The therapeutical gene may be, for example, an anti-tumor gene, a gene of an enzyme converting a prodrug into a drug, an antisense or SiRNA of a gene related to a tumor, or oncolytic virus (see Yip S et al., The Cancer J. 9(3), 189-204, 2003).

The UCB-MSC may be for example, an UCB-MSC that an anti-tumor agent gene is introduced thereinto. The anti-tumor agent gene may be for example, an agent selected from the group consisting of a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory factor gene and an angiogenesis inhibitor gene. The tumor suppressor gene may be a gene selected from the group consisting of a gene encoding phosphatase and tensin homolog (PTEN), a gene encoding Maspin, a gene encoding RUNX3, a gene encoding Caveolin-1, a gene encoding nm23, a gene encoding Rb protein, a gene encoding Brush-1, a gene encoding inhibitor of tumor growth (ING-4), a gene encoding survivin, a gene encoding X chromosome linked inhibitor apoptosis protein (XIAP), a gene encoding neural apoptosis inhibitory protein (NAIP), genes encoding proteins related to regulation of said genes and a combination thereof.

The PTEN gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tensin like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway. The PTEN may have an amino acid sequence of SEQ ID NO: 9. The PTEN gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 9.

Maspin (mammary serine proteinase inhibitor), a member of the serpin superfamily, has a multitude of effects on cells and tissues at an assortment of developmental stages. Maspin has tumor suppressing activity against breast and prostate cancer. The Maspin may have an amino acid sequence of SEQ ID NO: 10. The Maspin gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 10.

RUNX3 (RUNT-related transcription factor 3) gene encodes a member of the runt domain-containing family of transcription factors. A heterodimer of this protein and a beta subunit forms a complex that binds to the core DNA sequence 5′-PYGPYGGT-3′ found in a number of enhancers and promoters, and can either activate or suppress transcription. It also interacts with other transcription factors. It functions as a tumor suppressor, and the gene is frequently deleted or transcriptionally silenced in cancer. Multiple transcript variants encoding different isoforms have been found for this gene. The RUNX3 may have an amino acid sequence of SEQ ID NO: 11 (isoform 1) or 12 (isoform 2). The RUNX3 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 11 or 12.

Caveolin 1 (CAV1), a scaffolding protein, is the main component of the caveolae plasma membranes found in most cell types. The protein links integrin subunits to the tyrosine kinase FYN, an initiating step in coupling integrins to the Ras-ERK pathway and promoting cell cycle progression. The gene is a tumor suppressor gene candidate and a negative regulator of the Ras-p42/44 MAP kinase cascade. CAV1 and CAV2 are located next to each other on chromosome 7 and express colocalizing proteins that form a stable hetero-oligomeric complex. By using alternative initiation codons in the same reading frame, two isoforms (alpha and beta) are encoded by a single transcript from caveolin 1 gene. The CAVEOLIN 1 may have an amino acid sequence of SEQ ID NO: 13. The CAVEOLIN 1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 13.

NM23 gene (NME1; nonmetastatic cells 1, protein expressed in) was identified because of its reduced mRNA transcript levels in highly metastatic cells. Nucleoside diphosphate kinase (NDK) exists as a hexamer composed of ‘A’ (encoded by this gene) and ‘B’ (encoded by NME2) isoforms. Mutations in this gene have been identified in aggressive neuroblastomas. Two transcript variants encoding different isoforms have been found for this gene. Co-transcription of this gene and the neighboring downstream gene (NME2) generates naturally-occurring transcripts (NME1-NME2), which encodes a fusion protein comprised of sequence sharing identity with each individual gene product. The NM23 may have an amino acid sequence of SEQ ID NO: 14 (isoform A) or 15 (isoform B). The NM23 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 14 or 15.

The protein encoded by Rb (Retinoblastoma; Rb1) gene is a negative regulator of the cell cycle and was the first tumor suppressor gene found. The encoded protein also stabilizes constitutive heterochromatin to maintain the overall chromatin structure. The active, hypophosphorylated form of the protein binds transcription factor E2F1. Defects in this gene are a cause of childhood cancer retinoblastoma (RB), bladder cancer, and osteogenic sarcoma. The Rb may have an amino acid sequence of SEQ ID NO: 16. The Rb gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 16.

The protein encoded by Brush-1 (Myosin IA; MYOIA; BBMI) gene belongs to the myosin superfamily. Myosins are molecular motors that, upon interaction with actin filaments, utilize energy from ATP hydrolysis to generate mechanical force. Each myosin has a conserved N-terminal motor domain that contains both ATP-binding and actin-binding sequences. Following the motor domain is a light-chain-binding ‘neck’ region containing 1-6 copies of a repeat element, the IQ motif, that serves as a binding site for calmodulin or other members of the EF-hand superfamily of calcium-binding proteins. At the C-terminus, each myosin class has a distinct tail domain that serves in dimerization, membrane binding, protein binding, and/or enzymatic activities and targets each myosin to its particular subcellular location. The kidney epithelial cell line, LLC-PK1-CL4 (CL4), forms a well ordered brush border (BB) on its apical surface. Experiments indicate that the brush border population of the encoded protein turns over rapidly, while its head and tail domains interact transiently with the core actin and plasma membrane, respectively. A rapidly exchanging pool of the protein encoded by this gene envelops an actin core bundle that, by comparison, is static in structure. The Brush-1 may have an amino acid sequence of SEQ ID NO: 17. The Brush-1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 17.

ING4 (inhibitor of growth 4) gene encodes a tumor suppressor protein that contains a PHD-finger, which is a common motif in proteins involved in chromatin remodeling. This protein can bind TP53 and EP300/p300, a component of the histone acetyl transferase complex, suggesting its involvement in the TP53-dependent regulatory pathway. Multiple alternatively spliced transcript variants have been observed that encode distinct proteins. The ING4 may have an amino acid sequence of SEQ ID NO: 18 (isoform 1), 19 (isoform 3), 20 (isoform 4), 21 (isoform 5), 22 (isoform 6) or 23 (isoform 9). The ING4 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 18, 19, 20, 21, 22 or 23.

Survivin (Baculoviral IAP repeat-containing protein 5; BIRC5) gene is a member of the inhibitor of apoptosis (IAP) gene family, which encodes negative regulatory proteins that prevent apoptotic cell death. IAP family members usually contain multiple baculovirus IAP repeat (BIR) domains, but this gene encodes proteins with only a single BIR domain. The encoded proteins also lack a C-terminus RING finger domain. Gene expression is high during fetal development and in most tumors yet low in adult tissues. Antisense transcripts are involved in the regulation of this gene's expression. At least four transcript variants encoding distinct isoforms have been found for this gene, but the full-length natures of only three of them have been determined. The Survivin may have an amino acid sequence of SEQ ID NO: 24 (isoform 1), (isoform 2) or 26 (isoform 3). The Survivin gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 24, 25 or 26.

The protein encoded by XIAP (Inhibitor of apoptosis, X-linked; Baculoviral IAP repeat-containing protein 4; BIRC4) gene is a member of a family of proteins which inhibit apoptosis through binding to tumor necrosis factor receptor-associated factors TRAF1 and TRAF2. This protein inhibits apoptosis induced by menadione, a potent inducer of free radicals, and ICE. It also inhibits at least two members of the caspase family of cell-death proteases, caspase-3 and caspase-7. The XIAP may have an amino acid sequence of SEQ ID NO: 27. The XIAP gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 27.

NAIP (Neuronal apoptosis inhibitory protein; baculoviral IAP repeat-containing protein 1; BIRC) gene is part of a 500 kb inverted duplication on chromosome 5q13. This duplicated region contains at least four genes and repetitive elements which make it prone to rearrangements and deletions. The repetitiveness and complexity of the sequence have also caused difficulty in determining the organization of this genomic region. This copy of the gene is full length; additional copies with truncations and internal deletions are also present in this region of chromosome 5q13. It is thought that this gene is a modifier of spinal muscular atrophy caused by mutations in a neighboring gene, SMN1. The protein encoded by this gene contains regions of homology to two baculovirus inhibitor of apoptosis proteins, and it is able to suppress apoptosis induced by various signals. Alternatively spliced transcript variants encoding distinct isoforms have been found for this gene. The NAIP may have an amino acid sequence of SEQ ID NO: 28 (isoform 1) or SEQ ID NO: 29 (isoform 2). The NAIP gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 28 or 29.

The apoptosis inducing factor gene may be for example, a gene selected from the group consisting of a gene encoding cytokine, a gene encoding interleukin, a gene encoding a tumor necrosis factor (TNF), a gene encoding interferon (INF-α, INF-β, INF-γ), a gene encoding a colony stimulating factor (CSFs), a gene encoding p53, a gene encoding Apaf-1, a gene encoding TRAIL, a gene encoding Caspase, a gene encoding Bax, a gene encoding Bad, a gene encoding to FADD, a gene encoding JNK, a gene encoding p38 kinase and genes encoding proteins related to regulation of said genes.

TNF (tumor necrosis factor) gene encodes a multifunctional proinflammatory cytokine that belongs to the tumor necrosis factor (TNF) superfamily. This cytokine is mainly secreted by macrophages. It can bind to, and thus functions through its receptors TNFRSF1A/TNFR1 and TNFRSF1B/TNFBR. This cytokine is involved in the regulation of a wide spectrum of biological processes including cell proliferation, differentiation, apoptosis, lipid metabolism, and coagulation. This cytokine has been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. Knockout studies in mice also suggested the neuroprotective function of this cytokine. The TNF may have an amino acid sequence of SEQ ID NO: 30. The TNF gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 30.

INF-α, leukocyte interferon is produced predominantly by B lymphocytes. Immune interferon (IFN-gamma; MIM 147570) is produced by mitogen- or antigen-stimulated T lymphocytes. INF-β is produced by fibroblast. The INF-α may have an amino acid sequence of SEQ ID NO: 31. The INF-α gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 31. The INF-β may have an amino acid sequence of SEQ ID NO: 32. The INF-β gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 32. INF-γ or type II interferon is a cytokine critical for innate and adaptive immunity against viral and intracellular bacterial infections and for tumor control. Aberrant INF-γ expression is associated with a number of autoinflammatory and autoimmune diseases. The importance of INF-γ in the immune system stems in part from its ability to inhibit viral replication directly, but most importantly derives from its immunostimulatory and immunomodulatory effects. INF-γ is produced predominantly by natural killer (NK) and natural killer T (NKT) cells as part of the innate immune response, and by CD4 (MIM 186940) and CD8 (see MIM 186910) cytotoxic T lymphocyte (CTL) effector T cells once antigen-specific immunity develops. The INF-γ may have an amino acid sequence of SEQ ID NO: 33. The INF-γ gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 33.

The CSF may include CSF1, CSF2 or CSF3. CSF1 (COLONY-STIMULATING FACTOR 1) is a cytokine that controls the production, differentiation, and function of macrophages. The active form of the protein is found extracellularly as a disulfide-linked homodimer, and is thought to be produced by proteolytic cleavage of membrane-bound precursors. The encoded protein may be involved in development of the placenta. Four transcript variants encoding three different isoforms have been found for this gene. The CSF1 may have an amino acid sequence of SEQ ID NO: 34 (isoform a precursor), SEQ ID NO: 35 (isoform a precursor), SEQ ID NO: 36 (isoform b precursor) or SEQ ID NO: 37 (isoform c precursor). The CSF1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 34, 35, 36 or 37.

CSF2 is a cytokine that controls the production, differentiation, and function of granulocytes and macrophages. The active form of the protein is found extracellularly as a homodimer. CSF2 gene has been localized to a cluster of related genes at chromosome region 5q31, which is known to be associated with interstitial deletions in the 5q-syndrome and acute myelogenous leukemia. Other genes in the cluster include those encoding interleukins 4, 5, and 13. The CSF2 may have an amino acid sequence of SEQ ID NO: 38. The CSF2 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 38.

CSF3 is a cytokine that controls the production, differentiation, and function of granulocytes. The active protein is found extracellularly. Three transcript variants encoding three different isoforms have been found for this gene. The CSF3 may have an amino acid sequence of SEQ ID NO: 39 (isoform a precursor), SEQ ID NO: 40 (isoform b precursor), or SEQ ID NO: 41 (isoform c). The CSF3 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 39, 40, or 41.

P53 (Tumor protein p53; TP53) responds to diverse cellular stresses to regulate target genes that induce cell cycle arrest, apoptosis, senescence, DNA repair, or changes in metabolism. p53 protein is expressed at low level in normal cells and at a high level in a variety of transformed cell lines, where it's believed to contribute to transformation and malignancy. p53 is a DNA-binding protein containing transcription activation, DNA-binding, and oligomerization domains. It is postulated to bind to a p53-binding site and activate expression of downstream genes that inhibit growth and/or invasion, and thus function as a tumor suppressor. Mutants of p53 that frequently occur in a number of different human cancers fail to bind the consensus DNA binding site, and hence cause the loss of tumor suppressor activity. Alterations of this gene occur not only as somatic mutations in human malignancies, but also as germline mutations in some cancer-prone families with Li-Fraumeni syndrome. Multiple p53 variants due to alternative promoters and multiple alternative splicing have been found. These variants encode distinct isoforms, which can regulate p53 transcriptional activity. The p53 may have an amino acid sequence of SEQ ID NO: 42 (isoform a), SEQ ID NO: 43 (isoform a), SEQ ID NO: 44 (isoform to b), SEQ ID NO: 45 (isoform c), SEQ ID NO: 46 (isoform d), SEQ ID NO: 47 (isoform e) or SEQ ID NO: 48 (isoform f). The p53 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 42, 43, 44, 45, 46, 47 or 48.

APAF1 (apoptotic protease activating factor 1) is a cytoplasmic protein that initiates apoptosis. This protein contains several copies of the WD-40 domain, a caspase recruitment domain (CARD), and an ATPase domain (NB-ARC). Upon binding cytochrome c and dATP, this protein forms an oligomeric apoptosome. The apoptosome binds and cleaves caspase 9 preproprotein, releasing its mature, activated form. Activated caspase 9 stimulates the subsequent caspase cascade that commits the cell to apoptosis. Alternative splicing results in several transcript variants encoding different isoforms. The APAF1 may have an amino acid sequence of SEQ ID NO: 49 (isoform a), SEQ ID NO: 50 (isoform b), SEQ ID NO: 51 (isoform c), SEQ ID NO: 52 (isoform d), or SEQ ID NO: 53 (isoform e). The APAF1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 49, 50, 51, 52, or 53.

TRAIL (TNF-related apoptosis-inducing ligand; tumor necrosis factor ligand superfamily, member 10; TNFSF10) is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein preferentially induces apoptosis in transformed and tumor cells, but does not appear to kill normal cells although it is expressed at a significant level in most normal tissues. This protein binds to several members of TNF receptor superfamily including TNFRSF10A/TRAILR1, TNFRSF10B/TRAILR2, TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and possibly also to TNFRSF11B/OPG. The activity of this protein may be modulated by binding to the decoy receptors TNFRSF10C/TRAILR3, TNFRSF10D/TRAILR4, and TNFRSF11B/OPG that cannot induce apoptosis. The binding of this protein to its receptors has been shown to trigger the activation of MAPK8/JNK, caspase 8, and caspase 3. The TRAIL may have an amino acid sequence of SEQ ID NO: 54. The TRAIL gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 54.

Caspase 3 (apoptosis-related cysteine protease; CASP3) is a protein which is a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes which undergo proteolytic processing at conserved aspartic residues to produce two subunits, large and small, that dimerize to form the active enzyme. This protein cleaves and activates caspases 6, 7 and 9, and the protein itself is processed by caspases 8, 9 and 10. It is the predominant caspase involved in the cleavage of amyloid-beta 4A precursor protein, which is associated with neuronal death in Alzheimer's disease. Alternative splicing of this gene results in two transcript variants that encode the same protein. The Caspase 3 may have an amino acid sequence of SEQ ID NO: 55. The Caspase 3 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 55.

BAX (BCL2-associated X protein) belongs to the BCL2 protein family. BCL2 family members form hetero- or homodimers and act as anti- or pro-apoptotic regulators that are involved in a wide variety of cellular activities. This protein forms a heterodimer with BCL2, and functions as an apoptotic activator. This protein is reported to interact with, and increase the opening of, the mitochondrial voltage-dependent anion channel (VDAC), which leads to the loss in membrane potential and the release of cytochrome c. The expression of this gene is regulated by the tumor suppressor P53 and has been shown to be involved in P53-mediated apoptosis. Multiple alternatively spliced transcript variants, which encode different isoforms, have been reported for this gene. The BAX may have an amino acid sequence of SEQ ID NO: 56. The BAX gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 56.

BAD (BCL2 antagonist of cell death) is a member of the BCL-2 family. BCL-2 family members are known to be regulators of programmed cell death. This protein positively regulates cell apoptosis by forming heterodimers with BCL-xL and BCL-2, and reversing their death repressor activity. Proapoptotic activity of this protein is regulated through its phosphorylation. Protein kinases AKT and MAP kinase, as well as protein phosphatase calcineurin were found to be involved in the regulation of this protein. Alternative splicing of this gene results in two transcript variants which encode the same isoform. The BAD may have an amino acid sequence of SEQ ID NO: 57. The BAD gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 57.

FADD (FAS-associated via death domain) is an adaptor molecule that interacts with various cell surface receptors and mediates cell apoptotic signals. Through its C-terminal death domain, this protein can be recruited by TNFRSF6/Fas-receptor, tumor necrosis factor receptor, TNFRSF25, and TNFSF10/TRAIL-receptor, and thus it participates in the death signaling initiated by these receptors. Interaction of this protein with the receptors unmasks the N-terminal effector domain of this protein, which allows it to recruit caspase-8, and thereby activate the cysteine protease cascade. Knockout studies in mice also suggest the importance of this protein in early T cell development. The FADD may have an amino acid sequence of SEQ ID NO: 58. The FADD gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 58.

JNK1 (C-jun kinase 1; mitogen-activated protein kinase 8; MAPK8) is a member of the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. This kinase is activated by various cell stimuli, and targets specific transcription factors, and thus mediates immediate-early gene expression in response to cell stimuli. The activation of this kinase by tumor-necrosis factor alpha (TNF-alpha) is found to be required for TNF-alpha induced apoptosis. This kinase is also involved in UV radiation induced apoptosis, which is thought to be related to cytochrome c-mediated cell death pathway. Studies of the mouse counterpart of this gene suggested that this kinase play a key role in T cell proliferation, apoptosis and differentiation. Four alternatively spliced transcript variants encoding distinct isoforms have been reported. The JNK1 may have an amino acid sequence of SEQ ID NO: 59 (JNK1 alpha1), SEQ ID NO: 60 (JNK1 alpha2), SEQ ID NO: 61 (JNK1 beta 1) or SEQ ID NO: 62 (JNK1 beta2). The JNK1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 59, 60, 61 or 62.

P38 kinase (mitogen-activated protein kinase 14; MAPK14; p38 MAP KINASE; p38-ALPHA) is a member of the MAP kinase family. MAP kinases act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. This kinase is activated by various environmental stresses and proinflammatory cytokines. The activation requires its phosphorylation by MAP kinase kinases (MKKs), or its autophosphorylation triggered by the interaction of MAP3K71P1/TAB1 protein with this kinase. The substrates of this kinase include transcription regulator ATF2, MEF2C, and MAX, cell cycle regulator CDC25B, and tumor suppressor p53, which suggest the roles of this kinase in stress related transcription and cell cycle regulation, as well as in genotoxic stress response. Four alternatively spliced transcript variants of this gene encoding distinct isoforms have been reported. The p38 kinase may have an amino acid sequence of SEQ ID NO: 63 (isoform 1). The p38 kinase gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 63.

The cell cycle regulatory factor gene may be a gene selected from the group consisting of a gene encoding cdc2, a gene encoding Cyclin (Cyclin A, Cyclin D, Cyclin E), a gene encoding cdc25C, a gene encoding WAF, a gene encoding INK4, a gene encoding CDK (CDK1, CDK2, CDK4, CDK6), a gene encoding Rb protein, a gene encoding E2F, an antisense or siRNA thereof and genes encoding proteins related to the regulation of said genes.

CDC2 (cell division cycle 2, G1 to S and G2 to M; Cyclin-dependent kinase 1; CDK1) is a member of the Ser/Thr protein kinase family. This protein is a catalytic subunit of the highly conserved protein kinase complex known as M-phase promoting factor (MPF), which is essential for G1/S and G2/M phase transitions of eukaryotic cell cycle. Mitotic cyclins stably associate with this protein and function as regulatory subunits. The kinase activity of this protein is controlled by cyclin accumulation and destruction through the cell cycle. The phosphorylation and dephosphorylation of this protein also play important regulatory roles in cell cycle control. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. The CDC2 may have an amino acid sequence of SEQ ID NO: 64 (isoform 2). The CDC2 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 64.

Cyclin A (Cyclin A2; CCNA2) belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. In contrast to cyclin A1, which is present only in germ cells, this cyclin is expressed in all tissues tested. This cyclin binds and activates CDC2 or CDK2 kinases, and thus promotes both cell cycle G1/S and G2/M transitions. The Cyclin A may have an amino acid sequence of SEQ ID NO: 65. The Cyclin A gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 65.

The Cyclin D may include Cyclin D2, D3 or combination thereof. Cyclin D2 (CCND2) belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with and be involved in the phosphorylation of tumor suppressor protein Rb. Knockout studies of the homologous gene in mouse suggest the essential roles of this gene in ovarian granulosa and germ cell proliferation. High level expression of this gene was observed in ovarian and testicular tumors. The Cyclin D2 may have an amino acid sequence of SEQ ID NO: 66. The Cyclin D2 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 66. Cyclin D3 (CCND3) belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators to of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK4 or CDK6, whose activity is required for cell cycle G1/S transition. This protein has been shown to interact with and be involved in the phosphorylation of tumor suppressor protein Rb. The CDK4 activity associated with this cyclin was reported to be necessary for cell cycle progression through G2 phase into mitosis after UV radiation. Several transcript variants encoding different isoforms have been found for this gene. The Cyclin D3 may have an amino acid sequence of SEQ ID NO: 67. The Cyclin D3 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 67. The Cyclin E (CCNE; CYCLIN E1; CCNE1) belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance through the cell cycle. Cyclins function as regulators of CDK kinases. Different cyclins exhibit distinct expression and degradation patterns which contribute to the temporal coordination of each mitotic event. This cyclin forms a complex with and functions as a regulatory subunit of CDK2, whose activity is required for cell cycle G1/S transition. This protein accumulates at the G1-S phase boundary and is degraded as cells progress through S phase. Overexpression of this gene has been observed in many tumors, which results in chromosome instability, and thus may contribute to tumorigenesis. This protein was found to associate with, and be involved in, the phosphorylation of NPAT protein (nuclear protein mapped to the ATM locus), which participates in cell-cycle regulated histone gene expression and plays a critical role in promoting cell-cycle progression in the absence of pRB. Two alternatively spliced transcript variants of this gene, which encode distinct isoforms, have been described. Two additional splice variants were reported but detailed nucleotide sequence information is not yet available. The CYCLIN E may have an amino acid sequence of SEQ ID NO: 68. The Cyclin E gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 68.

CDC25C (cell division cycle 25C) gene is highly conserved during evolution and it plays a key role in the regulation of cell division. The CDC25C protein is a tyrosine phosphatase and belongs to the Cdc25 phosphatase family. It directs dephosphorylation of cyclin B-bound CDC2 and triggers entry into mitosis. It is also thought to suppress p53-induced growth arrest. Multiple alternatively spliced transcript variants of this gene have been described, however, the full-length nature of many of them is not known. The CDC25C may have an amino acid sequence of SEQ ID NO: 69 (isoform a) or SEQ ID NO: 70 (isoform b). The CDC25C gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 69 or 70.

WAF1 (wildtype p53-activated fragment 1; p21) is a potent cyclin-dependent kinase inhibitor. This protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli. This protein can interact with proliferating cell nuclear antigen (PCNA), a DNA polymerase accessory factor, and plays a regulatory role in S phase DNA replication and DNA damage repair. This protein was reported to be specifically cleaved by CASP3-like caspases, which thus leads to a dramatic activation of CDK2, and may be instrumental in the execution of apoptosis following caspase activation. Two alternatively spliced variants, which encode an identical protein, have been reported. The WAF1 may have an amino acid sequence of SEQ ID NO: 71. The CDC25C gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 71.

INK4 (Cyclin-dependent kinase inhibitor 2A; CDKN2A) gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, MDM1, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. The INK4 may have an amino acid sequence of SEQ ID NO: 72 (isoform 1), SEQ ID NO: 73 (isoform 3) or SEQ ID NO: 74 (isoform 4). The INK4 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 72, 73 or 74.

CDK2 (Cyclin-dependent kinase 2) is a member of the Ser/Thr protein kinase family. This protein kinase is highly similar to the gene products of S. cerevisiae cdc28, and S. pombe cdc2. It is a catalytic subunit of the cyclin-dependent protein kinase complex, whose activity is restricted to the G1-S phase, and essential for cell cycle G1/S phase transition. This protein associates with and regulated by the regulatory subunits of the complex including cyclin A or E, CDK inhibitor p21Cip1 (CDKN1A) and p27Kip1 (CDKN1B). Its activity is also regulated by its protein phosphorylation. Two alternatively spliced variants and multiple transcription initiation sites of this gene have been reported. The CDK2 may have an amino acid sequence of SEQ ID NO: 75 (isoform 1) or SEQ ID NO: 76 (isoform 2). The CDK2 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 75 or 76.

CDK4 (Cyclin-dependent kinase 4) is a member of the Ser/Thr protein kinase family. This protein is highly similar to the gene products of S. cerevisiae cdc28 and S. pombe cdc2. It is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression. The activity of this kinase is restricted to the G1-S phase, which is controlled by the regulatory subunits D-type cyclins and CDK inhibitor p16 (INK4a). This kinase was shown to be responsible for the phosphorylation of retinoblastoma gene product (Rb). Mutations in this gene as well as in its related proteins including D-type cyclins, p16 (INK4a) and Rb were all found to be associated with tumorigenesis of a variety of cancers. Multiple polyadenylation sites of this gene have been reported. The CDK4 may have an amino acid sequence of SEQ ID NO: 77. The CDK4 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 77.

CDK6 (Cyclin-dependent kinase 6) is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of Saccharomyces cerevisiae cdc28, and Schizosaccharomyces pombe cdc2, and are known to be important regulators of cell cycle progression. This kinase is a catalytic subunit of the protein kinase complex that is important for cell cycle G1 phase progression and G1/S transition. The activity of this kinase first appears in mid-G1 phase, which is controlled by the regulatory subunits including D-type cyclins and members of INK4 family of CDK inhibitors. This kinase, as well as CDK4, has been shown to phosphorylate, and thus regulate the activity of, tumor suppressor protein Rb. The CDK6 may have an amino acid sequence of SEQ ID NO: 78. The CDK6 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 78.

Transcription factor E2F (E2F Transcription factor 1; E2F1) is a member of the E2F family of transcription factors. The E2F family plays a crucial role in the control of cell cycle and action of tumor suppressor proteins and is also a target of the transforming proteins of small DNA tumor viruses. The E2F proteins contain several evolutionally conserved domains found in most members of the family. These domains include a DNA binding domain, a dimerization domain which determines interaction with the differentiation regulated transcription factor proteins (DP), a transactivation domain enriched in acidic amino acids, and a tumor suppressor protein association domain which is embedded within the transactivation domain. This protein and another 2 members, E2F2 and E2F3, have an additional cyclin binding domain. This protein binds preferentially to retinoblastoma protein pRB in a cell-cycle dependent manner. It can mediate both cell proliferation and p53-dependent/independent apoptosis. The E2F may have an amino acid sequence of SEQ ID NO: 79. The E2F gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 79.

The angiogenesis inhibitor gene may be a gene selected from the group consisting of a gene encoding thrombospondin-1, a gene encoding endostatin, a gene encoding tumstatin, a gene encoding canstatin, a gene encoding vastatin, a gene encoding restin, a gene encoding a vascular endothelial growth factor inhibitor, a gene encoding maspin, a gene encoding angiopoietins, a gene encoding 16-kd prolactin fragment and a gene encoding endorepellin.

Thrombospondin I (THBS1, TSP1)) is a subunit of a disulfide-linked homotrimeric protein. This protein is an adhesive glycoprotein that mediates cell-to-cell and cell-to-matrix interactions. This protein can bind to fibrinogen, fibronectin, laminin, type V collagen and integrins alpha-V/beta-1. This protein has been shown to play roles in platelet aggregation, angiogenesis, and tumorigenesis. The thrombospondin 1 may have an amino acid sequence of SEQ ID NO: 80. The thrombospondin 1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 80.

Endostatin is contained in collagen, type XVIII, alpha-1 (COL18A1) which is the alpha chain of type XVIII collagen. This collagen is one of the multiplexins, extracellular matrix proteins that contain multiple triple-helix domains (collagenous domains) interrupted by non-collagenous domains. The proteolytically produced C-terminal fragment of type XVIII collagen is endostatin, a potent antiangiogenic protein. Mutations in this gene are associated with Knobloch syndrome. The main features of this syndrome involve retinal abnormalities, so type XVIII collagen may play an important role in retinal structure and in neural tube closure. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. The Endostatin may have an amino acid sequence of SEQ ID NO: 81 (isoform 1) or 82 (isoform 2). The amino acid residues 1340-1510 of SEQ ID NO: 81 (isoform 1) or 1160-1330 residues of SEQ ID NO: 82 (isoform 2) is an endostatin like domain. The Endostatin gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 81 or 82.

Tumstatin is contained in collagen, type IV, alpha-3 (COL4A3). Type IV collagen, the major structural component of basement membranes, is a multimeric protein composed of 3 to alpha subunits. These subunits are encoded by 6 different genes, alpha 1 through alpha 6, each of which can form a triple helix structure with 2 other subunits to form type IV collagen. This gene encodes alpha 3. In the Goodpasture syndrome, autoantibodies bind to the collagen molecules in the basement membranes of alveoli and glomeruli. The epitopes that elicit these autoantibodies are localized largely to the non-collagenous C-terminal domain of the protein. A specific kinase phosphorylates amino acids in this same C-terminal region and the expression of this kinase is upregulated during pathogenesis. There are multiple alternate transcripts that appear to be unique to this human alpha 3 gene and alternate splicing is restricted to the six exons that encode this C-terminal domain. This gene is also linked to an autosomal recessive form of Alport syndrome. The mutations contributing to this syndrome are also located within the exons that encode this C-terminal region. Like the other members of the type IV collagen gene family, this gene is organized in a head-to-head conformation with another type IV collagen gene so that each gene pair shares a common promoter. Some exons of this gene are interspersed with exons of an uncharacterized gene which is on the opposite strand. The tumstatin may have an amino acid sequence of SEQ ID NO: 83. The tumstatin gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 83.

Canstatin (alpha 2 type IV collagen preproprotein) is one of the six subunits of type IV collagen, the major structural component of basement membranes. The C-terminal portion of the protein, known as canstatin, is an inhibitor of angiogenesis and tumor growth. Like the other members of the type IV collagen gene family, this gene is organized in a head-to-head conformation with another type IV collagen gene so that each gene pair shares a common promoter. The canstatin may have an amino acid sequence of SEQ ID NO: 84. The canstatin gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 84.

The restin (RSN, Reed-Steinbergcell-expressed intermediate filament-associated protein) may have an amino acid sequence of SEQ ID NO: 85. The restin gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 85. VEGI (vascular endothelial growth inhibitor; tumor necrosis factor ligand superfamily, member 15; TNFSF15) is a cytokine that belongs to the tumor necrosis factor (TNF) ligand family. This protein is abundantly expressed in endothelial cells, but is not expressed in either B or T cells. The expression of this protein is inducible by TNF and IL-1 alpha. This cytokine is a ligand for receptor TNFRSF25 and decoy receptor TNFRSF21/DR6. It can activate NF-kappaB and MAP kinases, and acts as an autocrine factor to induce apoptosis in endothelial cells. This cytokine is also found to inhibit endothelial cell proliferation, and thus may function as an angiogenesis inhibitor. An additional isoform encoded by an alternatively spliced transcript variant has been reported but the sequence of this transcript has not been determined. The VEGI may have an amino acid sequence of SEQ ID NO: 86. The VEGI gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 86. Angiopoietins are proteins with important roles in vascular development and angiogenesis. All angiopoietins bind with similar affinity to an endothelial cell-specific tyrosine-protein kinase receptor. The protein encoded by this gene is a secreted glycoprotein that activates the receptor by inducing its tyrosine phosphorylation. It plays a critical role in mediating reciprocal interactions between the endothelium and surrounding matrix and mesenchyme. The protein also contributes to blood vessel maturation and stability, and may be involved in early development of the heart. Angiopoietin 1 may have an amino acid sequence of SEQ ID NO: 87. The angiopoietin 1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 87.

Prolactin (PRL) may have an amino acid sequence of SEQ ID NO: 88. The prolactin gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 88.

The endorepellin may have an amino acid sequence of SEQ ID NO: 89. The endorepellin gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 89.

Further, the UCB-MSC may be for example, an UCB-MSC that a prodrug converting enzyme gene is introduced thereinto. The prodrug converting enzyme gene may be for example, a gene selected from cytosine deaminase gene, CYP2B1 gene and CYP2B6. The cytosine deaminase converte 5-FC into 5-FU that is an anticancer drug, or the cytochrome P-450 CYP2B1 enzyme, encoded by CYP2B1 gene, mediates the activation of at least one compounds selected from the group consisting of cyclophosphamide (CPA) and ifosfamide (IFO) to alkylating metabolites, which are anticancer drugs. The cytosine deaminase gene may include AICDA (activation-induced cytidine deaminase).

AICDA is a RNA-editing deaminase that is a member of the cytidine deaminase family. The protein is involved in somatic hypermutation, gene conversion, and class-switch recombination of immunoglobulin genes. Defects in this gene are the cause of autosomal recessive hyper-IgM immunodeficiency syndrome type 2 (HIGM2). The AICDA may have an amino acid sequence of SEQ ID NO: 90. The AICDA gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 90.

CYP2B6 (cytochrome P450, subfamily IIB, polypeptide 6) protein is a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by phenobarbital. The enzyme is known to metabolize some xenobiotics, such as the anti-cancer drugs cyclophosphamide and ifosphamide. Transcript variants for this gene have been described; however, it has not been resolved whether these transcripts are in fact produced by this gene or by a closely related pseudogene, CYP2B7. Both the gene and the pseudogene are located in the middle of a CYP2A pseudogene found in a large cluster of cytochrome P450 genes from the CYP2A, CYP2B and CYP2F subfamilies on chromosome 19q. The CYP2B6 may have an amino acid sequence of SEQ ID NO: 91. The CYP2B6 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 91.

In the method of the aspect of the present invention, the method further comprises administering a prodrug of an anticancer drug into the subject. The prodrug may be for example, 5-fluorocytosine (5-FC), which is a prodrug of 5-fluorouracil (5-FU), cyclophosphamide (CPA), ifosfamide (IFO) or a combination thereof.

The UCB-MSC may be for example, an UCB-MSC that an antisense or siRNA of a gene related to brain tumor is introduced thereinto. The gene related to brain tumor may be for example, a gene selected from the group consisting of a gene encoding a Ras family protein, a gene encoding c-myc, a gene encoding abl, a gene encoding erbB-1, a gene encoding EGFR, a gene encoding Bax, a gene encoding Apaf-1 interacting protein (APIP), a gene encoding Wnt-1-induced secreted protein 1 (WISP-1), a gene encoding Wnt, a gene encoding Raf-1, a gene encoding Src, a gene encoding Akt, a gene encoding Erk-1, 2 and a gene encoding BcL-2.

Myc (v-myc avian myelocytomatosis viral oncogene homolog) protein is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias and lymphomas, including Burkitt lymphoma. There is evidence to show that alternative translation initiations from an upstream, in-frame non-AUG (CUG) and a downstream AUG start site result in the production of two isoforms with distinct N-termini. The synthesis of non-AUG initiated protein is suppressed in Burkitt's lymphomas, suggesting its importance in the normal function of this gene. The Myc may have an amino acid sequence of SEQ ID NO: 92. The Myc gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 92.

Abl (abetalipoproteinemia) protein is the large subunit of the heterodimeric microsomal triglyceride transfer protein. Protein disulfide isomerase (PDI) completes the heterodimeric microsomal triglyceride transfer protein, which has been shown to play a central role in lipoprotein assembly. Mutations in MTP can cause abetalipoproteinemia. The abl may have an amino acid sequence of SEQ ID NO: 93. The abl gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 93.

ErbB1 (epidermal growth factor receptor; EGFR) is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. The erbB 1 may have an amino acid sequence of SEQ ID NO: 94 (isoform a precursor), SEQ ID NO: 95 (isoform d precursor) or SEQ ID NO: 96 (isoform b precursor). The erbB1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 94, 95 or 96.

APIP is an APAF1 (MIM 602233)-interacting protein that acts as a negative regulator of ischemic/hypoxic injury. The APIP may have an amino acid sequence of SEQ ID NO: 97. The APIP gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 97.

WISP1 (WNT1-inducible signaling pathway protein 1) is a member of the WNT1 inducible signaling pathway (WISP) protein subfamily, which belongs to the connective tissue growth factor (CTGF) family. WNT1 is a member of a family of cysteine-rich, glycosylated signaling proteins that mediate diverse developmental processes. The CTGF family members are characterized by four conserved cysteine-rich domains: insulin-like growth factor-binding domain, von Willebrand factor type C module, thrombospondin domain and C-terminal cystine knot-like domain. This gene may be downstream in the WNT1 signaling pathway that is relevant to malignant transformation. It is expressed at a high level in fibroblast cells, and overexpressed in colon tumors. The encoded protein binds to decorin and biglycan, two members of a family of small leucine-rich proteoglycans present in the extracellular matrix of connective tissue, and possibly prevents the inhibitory activity of decorin and biglycan in tumor cell proliferation. It also attenuates p53-mediated apoptosis in response to DNA damage through activation of the Akt kinase. It is 83% identical to the mouse protein at the amino acid level. Alternative splicing of this gene generates 2 transcript variants. The WISP1 may have an amino acid sequence of SEQ ID NO: 98 (isoform 1 precursor) or SEQ ID NO: 99 (isoform 2 precursor). The WISPI gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 98 or 99.

WNT1 (wingless-type MMTV integration site family, member 1) may have an amino acid sequence of SEQ ID NO: 100. The WNT1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 100. The WNT gene family consists of structurally related genes which encode secreted signaling proteins. These proteins have been implicated in oncogenesis and in several developmental processes, including regulation of cell fate and patterning during embryogenesis. This gene is a member of the WNT gene family. it is very conserved in evolution, and the protein encoded by this gene is known to be 98% identical to the mouse Wnt1 protein at the amino acid level. The studies in mouse indicate that the Wnt1 protein functions in the induction of the mesencephalon and cerebellum. This gene was originally considered as a candidate gene for Joubert syndrome, an autosomal recessive disorder with cerebellar hypoplasia as a leading feature. However, further studies suggested that the gene mutations might not have a significant role in Joubert syndrome. This gene is clustered with another family member, WNT10B, in the chromosome 12q13 region.

RAF1 (v-raf-1 murine leukemia viral oncogene homolog 1) is the cellular homolog of viral raf gene (v-raf). The protein is a MAP kinase kinase kinase (MAP3K), which functions downstream of the Ras family of membrane associated GTPases to which it binds directly. Once activated, the cellular RAF1 protein can phosphorylate to activate the dual specificity protein kinases MEK1 and MEK2, which in turn phosphorylate to activate the serine/threonine specific protein kinases, ERK1 and ERK2. Activated ERKs are pleiotropic effectors of cell physiology and play an important role in the control of gene expression involved in the cell division cycle, apoptosis, cell differentiation and cell migration. Mutations in this gene are associated with Noonan syndrome 5 and LEOPARD syndrome 2. Raf1 may have an amino acid sequence of SEQ ID NO: 101. The RAF1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 101.

Src (v-src avian sarcoma (SCHMIDT-RUPPIN A-2) viral oncogene) gene is highly similar to the v-src gene of Rous sarcoma virus. This proto-oncogene may play a role in the regulation of embryonic development and cell growth. The protein encoded by this gene is a tyrosine-protein kinase whose activity can be inhibited by phosphorylation by c-SRC kinase. Mutations in this gene could be involved in the malignant progression of colon cancer. Two transcript variants encoding the same protein have been found for this gene. SRC protein may have an amino acid sequence of SEQ ID NO: 102. The SRC gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 102.

Akt1 (v-ark murine thymoma viral oncogene homolog 1) protein may have an amino acid sequence of SEQ ID NO: 103. The Akt1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 103. The serine-threonine protein kinase encoded by the AKT1 gene is catalytically inactive in serum-starved primary and immortalized fibroblasts. AKT1 and the related AKT2 are activated by platelet-derived growth factor. The activation is rapid and specific, and it is abrogated by mutations in the pleckstrin homology domain of AKT1. It was shown that the activation occurs through phosphatidylinositol 3-kinase. In the developing nervous system AKT is a critical mediator of growth factor-induced neuronal survival. Survival factors can suppress apoptosis in a transcription-independent manner by activating the serine/threonine kinase AKT1, which then phosphorylates and inactivates components of the apoptotic machinery. Multiple alternatively spliced transcript variants have been found for this gene.

Erk1 (extracellular signal-regulated kinase 1; mitogen-activated protein kinase 3; MAPK3) protein is a member of the MAP kinase family. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act in a signaling cascade that regulates various cellular processes such as proliferation, differentiation, and cell cycle progression in response to a variety of extracellular signals. This kinase is activated by upstream kinases, resulting in its translocation to the nucleus where it phosphorylates nuclear targets. Alternatively spliced transcript variants encoding different protein isoforms have been described. Erk1 protein may have an amino acid sequence of SEQ ID NO: 104. The erk1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 104.

Erk2 (mitogen-activated protein kinase 1; MAPK1) protein is a member of the MAP kinase family. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals, and are involved in a wide variety of cellular processes such as proliferation, differentiation, transcription regulation and development. The activation of this kinase requires its phosphorylation by upstream kinases. Upon activation, this kinase translocates to the nucleus of the stimulated cells, where it phosphorylates nuclear targets. Two alternatively spliced transcript variants encoding the same protein, but differing in the UTRs, have been reported for this gene. Erk2 protein may have an amino acid sequence of SEQ ID NO: 105. The erk2 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 105.

BCL2 (B-cell CLL/lymphoma 2) gene encodes an integral outer mitochondrial membrane protein that blocks the apoptotic death of some cells such as lymphocytes. Constitutive expression of BCL2, such as in the case of translocation of BCL2 to Ig heavy chain locus, is thought to be the cause of follicular lymphoma. Two transcript variants, produced by alternate splicing, differ in their C-terminal ends. Bcl2 protein may have an amino acid sequence of SEQ ID NO: 106. The Bcl2 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 106.

Further, the UCB-MSC may be for example, an UCB-MSC that an oncolytic virus is introduced thereinto. The oncolytic virus may be a gene selected from Herpes simplex virus and Reovirus type 3.

In the method, the gene introduced in the UCB-MSC may be in an expressionable state. The UCB-MSCs to which a desired gene is introduced in an expressionable state can be appropriately manufactured using techniques that are known in the art. For example, a vector including a desired gene is prepared (see Dehari H et al., Cancer Gene Ther., 10, 75-85, 2003; WO07/037,653) and then the vector can be transduced ex vivo into primary culture MSCs. In this regard, examples of the vector include adenovirus vector, retrovirus vector, adeno-associated virus vector, herpes simplex virus vector, SV40 vector, poliomavirus vector, papillomavirus vector, picarnovirus vector, vaccinia virus vector, and lentivirus vector. For example, a method developed by Tsuda H et al. can be used (Mol Ther 2003, 7, 354-365). Specifically, one day before being infected with an adenovirus gene, MSCs for example, 5×10⁵ cells may be inoculated into a culture dish. Then the MSCs and a solution including an adenovirus vector to which the adenovirus gene is introduced are incubated at 37° C. in a 5% CO₂ incubator for 1 hour, so that the MSCs are infected with the adenovirus gene. Then the infected MSCs are washed with a phosphoric acid buffer solution and then a conventional medium is applied thereto. Alternatively, without use of a virus vector, a desired gene can be introduced into UCB-MSCs by using a naked DNA and any method selected from a calcium-phosphate method, a cationic liposome method, and an electrophoration method. Alternatively, a fusion protein gene of protein transduction domain (PTD) and anti-tumor protein can be introduced to UCB-MSCs using the fusion protein gene-including vector (see Wu S P et al. Biochem Biophys Res Commun. 346(1), 1-6, 2006).

The vectors may further include a gene marker for an additional histological examination. The gene marker may be, for example, a gene for coding a chromogenic or fluorescent protein, such as lacZ or a green fluorescent protein (GFP), but is not limited thereto (see Yip S et al., The Cancer J. 9(3), 189-204, 2003).

In the method, a cell of the tumor may be a cell expressing at least one gene selected from a group of a gene encoding IL-8, a gene encoding GRO-α and a combination thereof. The tumor may be for example, a tumor selected from the group consisting of a brain tumor, a liver hepatoma, a breast cancer, a colon cancer, a B-cell neoplasm and a combination thereof.

The brain tumor may be a primary brain tumor or secondary brain tumor. The brain tumor may be for example, a tumor selected from the group consisting of astrocytoma, pilocytic astrocytoma, low-grade astrocytoma, anaplastic astrocytoma, glioblastoma multiforme, brain stem cell glioma, ependymoma, subependymoma, ganglioneuroma, mixed glioma, oligodendroglioma, optic nerve glioma, acoustic neuroma, chordoma, CNS lymphoma, craniopharyngioma, hemangioblastoma, medulloblastoma, meningioma, pineal tumors, pituitary tumors, primitive neuroectodermal tumors, rhabdoid tumors, schwannoma, cysts, neurofibromatosis, pseudotumor cerebri, tuberous sclerosis and a combination thereof. The B-cell neoplasm cell may be for example, a cell selected from the group consisting of a common B acute lymphoblastic leukemia cell, a precursor B acute lymphoblastic leukemia cell, a B-cell chronic lymphocytic leukemia cell, a mantle cell lymphoma cell, a Burkitt's lymphoma cell, a Follicular lymphoma cell and a combination thereof.

In the method, the subject may an animal. The animal may a mammal, for example, a human.

In the method, the method may further comprise enhancing the gene selected from the group consisting of a gene encoding IL-8 receptor and a gene encoding GRO-α receptor at the UCB-MSC. The enhancement of the expression may be achieved by at least one selected from the group consisting of activating the endogenous gene, introducing an exogenous gene and a combination thereof. The introduction of a foreign gene into the UCB-MSC may be made by a known method in the art. The enhancement of the expression level of an endogenous gene, for example, achieved by amplifying the number of the endogenous gene or upregulating the expression of the endogenous gene by using any known method in the art.

The IL-8 protein is a member of the CXC chemokine family. This chemokine is one of the major mediators of the inflammatory response. This chemokine is secreted by several cell types. It functions as a chemoattractant, and is also a potent angiogenic factor. This gene is believed to play a role in the pathogenesis of bronchiolitis, a common respiratory tract disease caused by viral infection. This gene and other ten members of the CXC chemokine gene family form a chemokine gene cluster in a regionmapped to chromosome 4q. The IL-8 protein may have an amino acid sequence of SEQ ID NO: 107. The IL-8 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 107.

Chemokine (C-X-C motif) ligand 1 (CXCL1) is a small cytokine belonging to the CXC chemokine family that was previously called GRO1 oncogene, GROα, KC, Neutrophil-activating protein 3 (NAP-3) and melanoma growth stimulating activity, alpha (MSGA-α). In humans, this protein is encoded by CXCL1 gene. CXCL1 is secreted by human melanoma cells, has mitogenic properties and is implicated in melanoma pathogenesis. CXCL1 is expressed by macrophages, neutrophils and epithelial cells, and has neutrophil chemoattractant activity. CXCL1 plays a role in spinal cord development by inhibiting the migration of oligodendrocyte precursors and is involved in the processes of angiogenesis, inflammation, wound healing, and tumorigenesis. This chemokine elicits its effects by signaling through the chemokine receptor CXCR2. The gene for CXCL1 is located on human chromosome 4 amongst genes for other CXC chemokines. An initial study in mice showed evidence that CXCL1 decreased the severity of multiple sclerosis and may offer a neuro-protective function. The GROα protein may have an amino acid sequence of SEQ ID NO:108. The GROα gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO:108.

The IL-8 receptor may be for example, a receptor selected from a group consisting of CXCR1 and CXCR2. The GRO-α receptor may be a CXCR2.

The CXCR1 protein is a member of the G-protein-coupled receptor family. This protein is a receptor for interleukin-8 (IL-8). It binds to IL-8 with high affinity, and transduces the signal through a G-protein activated second messenger system. Knockout studies in mice suggested that this protein inhibits embryonic oligodendrocyte precursor migration in developing spinal cord. This gene, IL8RB, a gene encoding another high affinity IL-8 receptor, as well as IL8RBP, a pseudogene of IL8RB, form a gene cluster in a region mapped to chromosome 2q33-q36. The CXCR1 protein may have an amino acid sequence of SEQ ID NO: 109. The CXCR1 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 109.

The protein encoded by this gene is a member of the G-protein coupled receptor family. This protein is a receptor for interleukin-8 (IL-8). It binds to IL-8 with high affinity, and transduces the signal through a G-protein activated second messenger system. This receptor also binds to chemokine (C-X-C motif) ligand 1 (CXCL1/MGSA), a protein with melanoma growth stimulating activity, and has been shown to be a major component required for serum-dependent melanoma cell growth. In addition, it binds ligands CXCL2, CXCL3, and CXCL5. This receptor mediates neutrophil migration to sites of inflammation. The angiogenic effects of IL-8 in intestinal microvascular endothelial cells are found to be mediated by this receptor. Knockout studies in mice suggested that this receptor controls the positioning of oligodendrocyte precursors in developing spinal cord by arresting their migration. This gene, IL8RA, a gene encoding another high affinity IL-8 receptor, as well as IL8RBP, a pseudogene of IL8RB, form a gene cluster in a region mapped to chromosome 2q33-q36. The CXCR2 protein may have an amino acid sequence of SEQ ID NO: 110. The CXCR2 gene may have a nucleotide sequence encoding the amino acid sequence of SEQ ID NO: 110.

In the method, the term “an effective dose” refers to that amount which provides a preventative or therapeutic effect for a tumor condition and administration regimen without causing serious toxic effects in the subject treated. The effective dose may be determined by a person having an ordinary skill in the art. For example, the effective dose may be 1×10⁴ to 1×10⁷ cells/kg body weight, preferably 5×10⁵ to 5×10⁶ cells/kg body weight.

Another aspect of the present invention provides a kit for identifying the location and the size of a brain tumor, comprising UCB-MSC, said UCB-MSC being labeled with a detectable marker. The UCB-MSC and a brain tumor may be an UCB-MSC and a brain tumor as described above in this specification, respectively. The detectable marker may be any marker capable of producing a detectable signal. The UCB-MSCs labeled with the detectable marker can be visualized by a state-of-the-art technique, and can be tracked in real time in a live animal. For example, the detectable marker may a marker selected from luciferase-containing enzyme-based fluorescent detector and Tat peptide-derivatized magnetic nanoparticles (Yip S et al., The Cancer J. 9(3), 189-204, 2003). If a stem cell expressing luciferase is used, the administered stem cell migrating to the site of disease can be tracked by identifying bioluminescence in real time and thus, diseases can be diagnosed and the site of disease can be identified (see Weissleder R et al., Nat Med 9, 123-128, 2003). The bioluminescence using luciferase may containing administering a luciferin, a substrate of luciferase to the subject. Tat peptide-derivatized magnetic nanoparticles are connected to UCB-MSCs using a method developed by Lewin et al. (see Nat Biotech 18, 410-414, 2000) and then administered in vivo. The administered UCB-MSCs can be tracked by magnetic resonance imaging (MRI) to the nanoparticles. Accordingly, UCB-MSCs labeled with the Tat peptide-derivatized magnetic nanoparticles can be administered in vivo and then, by identifying a location where UCB-MSCs gather, the tumor and the site of the tumor can be identified. In addition, UCB-MSCs labeled with the marker can be administered during the brain tumor treatment or after the brain tumor treatment to identify the location and size of the distribution of the administered UCB-MSCs.

Another aspect of the present invention provides a method of identifying the location and the size of a brain tumor of a subject, wherein the method comprises:

(a) administering to the subject an UCB-MSC; (b) identifying the location and the size of the distribution of the administered UCB-MSC.

In the method of another aspect of the present invention, the method includes administering to the subject an UCB-MSC.

The administration may be made by using any known method in the art. For example, the administration may be made by a parenteral administration. The parenteral administration includes an injection. The injection may be made intravascullary, intramuscularly, subcutaneously, intradermally, or intrathecally. The administration may be made systemically or locally. The local administration may include direct administration to the tumor tissue.

The subject may an animal. The animal may a mammal, for example, a human. The UCB-MSC may be an UCB-MSC as described herein above. The UCB-MSC may be labeled with a detectable marker and detected as described herein above.

In the method of another aspect of the present invention, the method includes identifying the location and the size of the distribution of the administered UCB-MSC.

The identification of the location and the size of the distribution of the administered UCB-MSC may be made by detecting or measuring the signal from the administered UCB-MSC. The signal may be a signal derived from the detectable marker labeled. The signal may be a light or electrical signal. The light signal may include a visible light, UV or infrared light. The detection or measurement may be made by any known method for example, microscope observation, visual observation, or electronic or electrical detection.

Another aspect of the present invention provides a method of monitoring a progression of a tumor treatment in a subject who is received the brain tumor treatment, wherein the method comprises:

-   -   (a) first administering to the subject an UCB-MSC;     -   (b) identifying the location and the size of the distribution of         the first administered UCB-MSC in the subject;     -   (c) second administering to the subject an UCB-MSC;     -   (d) identifying the location and the size of the distribution of         the second administered UCB-MSC in the subject;     -   (e) comparing the location and the size of the distribution         identified by (b) and (d),         -   wherein the subject receives a treatment of the tumor during             the period starting from the first administration of the             UCB-MSC to the second administration of the UCB-MSC.

In the method of another aspect of the present invention, the method includes first administering to the subject UCB-MSC. The administration may be made by using any known method in the art as described herein above. For example, the administration may be made by a parenteral administration. The parenteral administration includes an injection. The injection may be made intravascullary, intramuscularly, subcutaneously, intradermally, or intrathecally. The administration may be made systemically or locally. The local administration may include direct administration to the tumor tissue. The UCB-MSC may be an UCB-MSC as described in herein above. The UCB-MSC are labeled with a detectable marker and detected as described herein above. The detectable marker may be any marker capable of producing a detectable signal. For example, the detectable marker may be a marker selected from luciferase-containing enzyme-based fluorescent detector and Tat peptide-derivatized magnetic nanoparticles (Yip S et al., The Cancer J. 9(3), 189-204, 2003). The subject may be an animal. The animal may be a mammal, for example, a human.

to The method further includes identifying in the subject. The identification of the location and the size of the distribution of the first administered UCB-MSC may be made as described in the above in this specification.

The method further includes second administering to the subject UCB-MSC. The administration, the subject and UCB-MSC may be the same as described in the above in this specification. The first UCB-MSC and second UCB-MSC may be derived from the same or different sources of umbilical cords bloods. The second may be made in the same way or different way as the first administration.

The method further includes identifying the location and the size of the distribution of the second administered UCB-MSC in the subject. The identification of the location and the size of the distribution of the first administered UCB-MSC may be made as described in the above in this specification.

The method further includes comparing the location and the size of the distribution identified by (b) and (d). The comparison may be made for example, by visually comparing the visual data by (b) and (d) or by comparing the digital data by (b) and (d), respectively.

In the method, the treatment of the tumor may be any cancer therapy. The treatment may include for example, a treatment selected from the group consisting of chemotherapy, radiotherapy, surgery and a combination thereof.

In the method, if the identified location and the size of the distribution of the second administered UCB-MSC in the subject is smaller than that of the first administered UCB-MSC, the progression of the treatment may be determined as successful, or if the identified location and the size of the distribution of the second administered UCB-MSC in the subject is same or larger than that of the first administered UCB-MSC, the progression of the treatment may be determined as not successful.

Another aspect of the present invention provides a method for delivering a therapeutic gene to a site of a subject, the site comprising cells expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cells, wherein the method comprises the step of administering to the subject an effective dose of the UCB-MSC.

The method includes the step of administering to the subject an effective dose of the to UCB-MSC. The administration, the subject and the UCB-MSC are as described in the above in this specification. The term “an effective dose” refers to that amount which delivers a therapeutic gene to a site of a subject comprising cells expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cells without causing serious toxic effects in the subject treated. The effective dose may be determined by a person having an ordinary skill in the art. For example, the effective dose may be 1×10⁴-1×10⁷ cells/kg body weight.

The UCB-MSC may be an UCB-MSC which a therapeutic gene is introduced into the UCB-MSC. The therapeutic gene may be for example, a gene selected from the group consisting of a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory gene and an angiogenesis inhibitor gene. Further, The UCB-MSC may be for example, an UCB-MSC that a prodrug converting enzyme gene is introduced to the UCB-MSC. The tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory gene, an angiogenesis inhibitor gene and prodrug converting enzyme gene may be the same as described in the above in this specification.

In the method of another aspect of the present invention, the method may further comprise administering a prodrug of an anticancer drug into the subject. The prodrug may be for example, 5-fluorocytosine (5-FC), which is a prodrug of 5-fluorouracil (5-FU). The administration and the subject may be as described in the above in this specification.

The UCB-MSC may be for example, an UCB-MSC an antisense or siRNA of a gene related to brain tumor is introduced thereinto. The gene related to brain tumor may be a gene selected from the group consisting of a gene encoding a Ras family protein, a gene encoding c-myc, a gene encoding abl, a gene encoding erbB-1, a gene encoding EGFR, a gene encoding Bax, a gene encoding Apaf-1 interacting protein (APIP), a gene encoding Wnt-1-induced secreted protein 1 (WISP-1), a gene encoding Wnt, a gene encoding Raf-1, a gene encoding Src, a gene encoding Akt, a gene encoding Erk-1,2 and a gene encoding BcL-2.

Further, the UCB-MSC may be for example, an UCB-MSC an oncolytic virus is introduced thereinto. The oncolytic virus may be a gene selected from Herpes simplex virus and Reovirus type 3.

In the method of the aspect of the present invention, the brain tumor may be for example, a tumor selected from the group consisting of astrocytoma, pilocytic astrocytoma, low-grade astrocytoma, anaplastic astrocytoma, glioblastoma multiforme, brain stem cell glioma, ependymoma, subependymoma, ganglioneuroma, mixed glioma, oligodendroglioma, optic nerve glioma, acoustic neuroma, chordoma, CNS lymphoma, craniopharyngioma, hemangioblastoma, medulloblastoma, meningioma, pineal tumors, pituitary tumors, primitive neuroectodermal tumors, rhabdoid tumors, schwannoma, cysts, neurofibromatosis, pseudotumor cerebri and tuberous sclerosis.

In the method of the aspect of the present invention, the subject may an animal. The animal may be a mammal, for example, a human.

In the method, the cell expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cells may be for example, a cell selected from the group consisting of a brain tumor cell, a hepatoma cell, a breast cancer cell, a lung cell with an acute respiratory distress syndrome, a colon cancer cell, a B-cell neoplasm cell and a combination thereof.

The brain tumor may be for example, a tumor selected from the group consisting of astrocytoma, pilocytic astrocytoma, low-grade astrocytoma, anaplastic astrocytoma, glioblastoma multiforme, brain stem cell glioma, ependymoma, subependymoma, ganglioneuroma, mixed glioma, oligodendroglioma, optic nerve glioma, acoustic neuroma, chordoma, CNS lymphoma, craniopharyngioma, hemangioblastoma, medulloblastoma, meningioma, pineal tumors, pituitary tumors, primitive neuroectodermal tumors, rhabdoid tumors, schwannoma, cysts, neurofibromatosis, pseudotumor cerebri and tuberous sclerosis. The B-cell neoplasm cell may be for example, a cell selected from the group consisting of a common B acute lymphoblastic leukemia cell, a precursor B acute lymphoblastic leukemia cell, a B-cell chronic lymphocytic leukemia cell, a mantle cell lymphoma cell, a Burkitt's lymphoma cell, a Follicular lymphoma cell and a combination thereof.

Another aspect of the present invention provides a kit for identifying the location and the size of a site of a subject, the site comprising cells expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cells, wherein the kit comprises UCB-MSC, the UCB-MSC are labeled with a detectable marker. The UCB-MSC and the detectable marker are as described in the above in this specification. The labeled UCB-MSC may be detected as described in the above in this specification. The marker may be located within nucleoplasm, within cytoplasm, within a cellular organelle or on or within the cell membrane.

In the kit, the cells expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cells may be for example, a cell selected from the group consisting of a brain tumor cell, a hepatoma cell, a breast cancer cell, a lung cell with an acute respiratory distress syndrome, a colon cancer cell, a B-cell neoplasm cell and a combination thereof.

The brain tumor may be for example, a tumor selected from the group consisting of astrocytoma, pilocytic astrocytoma, low-grade astrocytoma, anaplastic astrocytoma, glioblastoma multiforme, brain stem cell glioma, ependymoma, subependymoma, ganglioneuroma, mixed glioma, oligodendroglioma, optic nerve glioma, acoustic neuroma, chordoma, CNS lymphoma, craniopharyngioma, hemangioblastoma, medulloblastoma, meningioma, pineal tumors, pituitary tumors, primitive neuroectodermal tumors, rhabdoid tumors, schwannoma, cysts, neurofibromatosis, pseudotumor cerebri and tuberous sclerosis. The B-cell neoplasm cell may be for example, a cell selected from the group consisting of a common B acute lymphoblastic leukemia cell, a precursor B acute lymphoblastic leukemia cell, a B-cell chronic lymphocytic leukemia cell, a mantle cell lymphoma cell, a Burkitt's lymphoma cell and a Follicular lymphoma cell.

Another aspect of the present invention provides a method of identifying the location and the size of a site of a subject, the site comprising cells expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cells, wherein the method comprises:

(a) administering to the subject an UCB-MSC;

(b) identifying the location and the size of the distribution of the administered UCB-MSC.

The method includes administering to the subject an UCB-MSC. The administration, the subject and the UCB-MSC may be the same as described in the above in this specification. The UCB-MSC may be labeled with a detectable marker and detected as described in above in this specification. The marker may be located within nucleoplasm, within cytoplasm, within a cellular organelle or on or within the cell membrane.

The cell expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cell may be for example a cell selected from the group consisting of a brain tumor cell, a hepatoma cell, a breast cancer cell, a lung cell with an acute respiratory distress syndrome, a colon cancer cell and a B-cell neoplasm cell. The brain tumor and B-cell neoplasm cell are the same as described in the above in this specification.

Another aspect of the present invention provides a method of monitoring treatment progression of a disease occurred in a site of a subject, the site comprising cells expressing at least one selected from groups consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC, wherein the method comprises:

-   -   (a) first administering to the subject an UCB-MSC;     -   (b) identifying the location and the size of the distribution of         the first administered UCB-MSC in the subject;     -   (c) second administering to the subject an UCB-MSC;     -   (d) identifying the location and the size of the distribution of         the second administered UCB-MSC in the subject; and     -   (e) comparing the location and the size of the distribution         identified by (b) and (d), wherein the subject receives a         treatment of the disease during the period starting from the         first administration of the UCB-MSC to the second administration         of the UCB-MSC.

In the method of another aspect of the present invention, the method includes first administering to the subject an UCB-MSC. The administration, the subject and the UCB-MSC may be the same described in the above in this specification. The UCB-MSC are labeled with a detectable marker and detected as described in the above in this specification.

The method further includes identifying the location and the size of the distribution of the first administered UCB-MSC in the subject. The identification of the location and the size of the distribution of the first administered UCB-MSC may be made as described in the above in this specification.

The method further includes second administering to the subject UCB-MSC. The administration, the subject and UCB-MSC may be the same as described in the above in this specification. The first UCB-MSC and second UCB-MSC may be derived from the same or different sources of umbilical cord bloods. The second administration may be made in the same way or different way as the first administration. The second UCB-MSC may be labeled with a detectable marker. The detectable marker is as described in the above. The detectable marker used in the second UCB-MSC may be the same with or different from that used in the first UCB-MSC.

The method further includes identifying the location and the size of the distribution of the second administered UCB-MSC in the subject. The identification of the location and the size of the distribution of the first administered UCB-MSC may be made as described in the above in this specification.

The method further includes comparing the location and the size of the distribution identified by (b) and (d). The comparison may be made for example, by visually comparing the visual data from (b) and (d) or by comparing the digital data from (b) and (d), respectively.

In the method, the disease may be any disease caused by cells expressing, for example, overexpressing at least one selected from groups consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC.

The treatment of the disease may be any cancer therapy. The treatment may include for example, a treatment selected from the group consisting of chemotherapy, radiotherapy, surgery and a combination thereof.

In the method, if the identified location and the size of the distribution of the second administered UCB-MSC in the subject is smaller than that of the first administered UCB-MSC, the progression of the treatment may be determined as successful, or if the identified location and the size of the distribution of the second administered UCB-MSC in the subject is the same or larger than that of the first administered UCB-MSC, the progression of the treatment may be determined as not successful.

In the method, the cell expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cell may be for example, a cell selected from the group consisting of a brain tumor cell, a hepatoma cell, a breast cancer cell, a lung cell with an acute respiratory distress syndrome, a colon cancer cell and a B-cell neoplasm cell. The B-cell neoplasm cell may be for example a cell selected from the group consisting of a common B acute lymphoblastic leukemia cell, a precursor B acute lymphoblastic leukemia cell, a B-cell chronic lymphocytic leukemia cell, a mantle cell lymphoma cell, a Burkitt's lymphoma cell and a Follicular lymphoma cell.

Another aspect of the present invention provides a method of delivering an anti-tumor agent to a site of a tumor in a subject, which comprises administering mesenchymal stem cells together with the anti-tumor agent to the site, wherein the mesenchymal stem cells (MSCs) are umbilical cord blood-derived MSCs (“UCB-MSC”).

The administration and UCB-MSC may be as described in the above in this specification. The MSCs may be used in an amount of 1×10⁴-1×10⁷ cells/kg body weight. The anti-tumor agent may be any anti-tumor agent known in the art. The anti-tumor agent may be an agent selected from the group consisting of a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory factor gene and an angiogenesis inhibitor gene. The anti-tumor agent may be admixed with the UCB-MSCs or be carried within the UCB-MSCs. The anti-tumor agent may be introduced into the UCB-MSCs by using any known introduction method of a foreign nucleic acid in the art. The introduction method may be for example, electroporation, transformation, transfection and bombardment.

In the method, the tumor may be a brain tumor. The brain tumor may be a tumor selected from the group consisting of astrocytoma, pilocytic astrocytoma, low-grade astrocytoma, anaplastic astrocytoma, glioblastoma multiforme, brain stem glioma, ependymoma, subependymoma, ganglioneuroma, mixed glioma, oligodendroglioma, optic nerve glioma, acoustic neuroma, chordoma, CNS lymphoma, craniopharyngioma, hemangioblastoma, medulloblastoma, meningioma, pineal tumors, pituitary tumors, primitive neuroectodermal tumors, rhabdoid tumors, schwannoma, cysts, neurofibromatosis, pseudotumor cerebri, tuberous sclerosis and a combination thereof.

The tumor suppressor gene may be a gene selected from the group consisting of phosphatase and tensin homolog gene (PTEN), Maspin gene, RUNX3 gene, Caveolin-1 gene, nm23 gene, Rb protein gene, Brush-1 gene, a gene encoding an inhibitor of tumor growth (ING-4), surviving gene, X chromosome linked inhibitor apoptosis protein (XIAP) gene, neural apoptosis inhibitory protein (NAIP) gene and genes encoding a protein related to regulating said genes. The apoptosis inducing factor gene may be a gene selected from the group consisting of a gene encoding cytokine, a gene encoding interleukin, a gene encoding a tumor necrosis factor (TNF), a gene encoding interferon (INF-α, INF-β, INF-γ), a gene encoding a colony stimulating factor (CSFs), a gene encoding p53, a gene encoding Apaf-1, a gene encoding TRAIL, a gene encoding Caspase, a gene encoding Bax, a gene encoding Bad, a gene encoding FADD, a gene encoding INK, a gene encoding p38 kinase and genes encoding proteins related to regulating said genes. The cell cycle regulatory factor gene may be a gene selected from the group consisting of a gene encoding cdc2, a gene encoding Cyclin (Cyclin A, Cyclin D, Cyclin E), a gene encoding cdc25C, a gene encoding WAF, a gene encoding INK4, a gene encoding CDK (CDK1, CDK2, CDK4, CDK6), a gene encoding Rb protein, a gene encoding E2F, an antisense or siRNA thereof and genes encoding proteins related to regulating said genes. The angiogenesis inhibitor gene may be a gene selected from the group consisting of a gene encoding thrombospondin-1, a gene encoding endostatin, a gene encoding tumstatin, a gene encoding canstatin, a gene encoding vastatin, a gene encoding restin, a gene encoding a vascular endothelial growth factor inhibitor, a gene encoding maspin, a gene encoding angiopoietins, a gene encoding 16-kd prolactin fragment and a gene encoding endorepellin.

Further, the anti-tumor agent may be a prodrug converting enzyme gene.

Further, the anti-tumor agent may be for example, an antisense or siRNA of a gene related to a brain tumor. The gene related to brain tumor may be for example a gene selected from the group consisting of a gene encoding Ras family, a gene encoding c-myc, a gene encoding abl, a gene encoding erbB-1, a gene encoding EGF-R, a gene encoding Bax, a gene encoding Apaf-1 interacting protein (APIP), a gene encoding Wnt-1-induced secreted protein 1 (WISP-1), a gene encoding Wnt, a gene encoding Raf-1, a gene encoding Src, a gene encoding Akt, a gene encoding Erk-1,2 and a gene encoding BcL-2. The anti-tumor agent may be an oncolytic virus. The oncolytic virus may be a virus selected from Herpes simplex virus and Reovirus type 3.

In the present specification, the term “umbilical cord blood” refers to blood taken from an umbilical vein connecting a placenta to a fetus in all mammals including humans.

In the present specification, the term “umbilical cord blood-derived mesenchymal stem cells (“UCB-MSC”) as used throughout the application is defined as mesenchymal stem cells that are isolated from UCB, expanded from the MSCs isolated from the UCB, or a mixture thereof, and a culture containing such expanded MSCs”. The UCB-MSC may be derived from umbilical cord blood of mammals, preferably humans.

In the present specification, the term “treatment” refers to preventing disease or disorder development in an animal, preferably a mammal, and more preferably humans which are not yet diagnosed with but susceptible to a disease; suppressing disease progression; and alleviating disease.

In the present specification, the term “brain tumor” refers to a malignant or benign tumor developing in the brain and the spinal cord and all kinds of tumors developing in a glial cell and a non-glial cell. In this regard, the brain tumor may be a primary brain tumor or a secondary brain tumor.

Meanwhile, terms which are not defined in the present specification may have meanings which are conventionally defined in the art.

It is noted that all the prior art referred to in the present specification is incorporated by reference in its entirety.

The present invention will be described in further detail with reference to the following examples. These examples are for illustrative purposes only and are not intended to limit the scope of the present inventive concept.

EXAMPLES

U-87 MG, A549, KATO III, PLC/PRF5, LN18, U138 and U251 cell lines were purchased from American Type Culture Collection (ATCC) and used in the present experiments. A549, KATOIII and PLC/PRF5 cells were cultured in RPMI containing 10-20% (v/v) FBS (HyClone, Logan, Utah, US) and Gentamicin at 37° C. in a 5% CO₂ incubator. U-87 MG, LN18, U138 and U251 cells were grown in an Eagle's minimum essential medium (MEM) containing 10-20% (v/v) FBS. Bone marrow-derived mesenchymal stem cell (BM-MSCs) was purchased from LONZA. BM-MSCs and established UCB-MSCs were cultured in α-MEM media containing 10-20% FBS.

Example 1 Preparation of Umbilical Cord Blood-Derived Mesenchymal Stem Cells (UCB-MSCS)

UCB samples were collected from the umbilical vein of deliveries, with informed maternal consent. Specifically, a 16-gauge needle of a UCB collection bag containing 44 mL of CPDA-1 anticoagulant (Greencross Co., Yongin, Kyungki-do, Korea) was inserted into the umbilical vein and UCB was collected by gravity. In all cases, UCB harvests were processed within 48 hours of collection, with viability of 90% or more.

Example 2 Isolation and Expansion of UCB-MSCs

UCB-MSCs prepared according to Example 1 were centrifuged with a Ficoll-Hypaque gradient (produced by Sigma Co., density: 1.077 g/mL), and then washed several times to to remove impurities. 10 to 20% FBS (HyClone Co.)-containing a basic medium (α-MEM, Gibco BRL Co.) was added to the resultant product to suspend UCB-MSCs. The UCB-MSCs were portioned at a suitable concentration into each of 10 to 20% FBS—containing a basic media, and then cultivated at 37° C. in a 5% CO₂ incubator while the medium was altered twice in a week (FIG. 1). When the cultured cells formed a single layer, MSCs expanding in a spindle shape were identified with a phase-contrast microscope. Then, sub-cultivation was repeatedly performed until the MSCs expanded sufficiently.

Example 3 Preparation of UCB-MSCs Labeled with PKH-26

UCB-MSCs cultivated according to Example 2 were dyed with PKH-26 (Sigma Co.) using a method disclosed in a reference [Barreda D A et al., Developmental and Comparative Immunology, 24:395-406, 2000]. First, UCB-MSCs were separated from the cell culture dish by using Trypsin and then, 2×10⁷ cells were washed with an FBS-free medium. The washed cells were collected using a centrifuge and then suspended in 1 mL of Diluent C in a kit provided by a manufacturer. Then the resultant cell suspension solution (2×) was mixed with 1 ml of the PKH fluorescent dye solution(2×) and then the mixture was reacted at 25° C. for 5 minutes. To terminate the labeling reaction, a medium containing an equal volume of fetal bovine serum (FBS) was added to the reaction product and then left to sit for 1 minute. Cells labeled with PKH26 were collected by centrifuging and then, washed with a 10 to 20% FBS-containing medium three times and used in experiments.

Example 4 Co-Culture of MSCs and Other Cell Lines in Transwell Chamber

Human UCB-MSCs (hUCB-MSCs) were dyed with PKH-26 (produced by Sigma). The dyed hUCB-MSCs and other tumor cell lines were co-cultured under a culture condition in a transwell chamber (FALCON) (MSC: cancer cell lines=1:5). For a control group, cancer cell lines-free MSCs were cultured in the same condition as described above. The transwell chamber used in the co-culturing, as illustrated in FIG. 2, included a lower compartment and an upper compartment, wherein the lower compartment is separated from the upper compartment by a microporous membrane (8 μm size.) In the upper compartment, PKH26-labeled hUCB-MSCs were cultured; and in lower compartment, each of human brain tumor cell line U-87 MG, human rectal cancer cell line LS174-T, human B lymphocyte NC-37, and mouse's fibroblast NIH3T3 was cultured. After co-culturing for one day, two days, and three days each, the migration of PKH26-labeled UCB-MSCs was identified using a phase-contrast microscope (×100) and PKH26-labeled UCB-MSCs migrated was counted (FIG. 3). The same experiment was performed using KATO III, A549, PLC/PRF5, LN18, U138, and U251 which are tumor cell lines and the migration of PKH26-labeled UCB-MSCs was identified. The same experiment was performed in a condition in which a medium conditioned by U-87 MG cells was placed in the lower compartment (FIG. 4).

That is, PKH26-labeled UCB-MSCs were co-cultured with various tumor cell lines in a transwell chamber and then, PKH-labeled mesenchymal stem cells that have migrated into the lower compartment were counted. As a result, UCB-MSCs had a strong tropism for U-87 MG, LN18, U138, and U251 that are brain tumor cell lines, and a weak tropism for other tumor cells (FIGS. 3 and 4). In B of FIG. 3, the left image shows the case of the control group in which a human cell line-free medium was added instead of tumor cells, and the right image shows the case in which UCB-MSCs were co-cultured with U-87 MG cell. Referring to FIG. 3, the migration of many PKH26-labeled UCB-MSCs was identified. When the human cell line-free medium was used instead of tumor cells and cultured, the migration of PKH26-labeled UCB-MSCs was negligible (see the left image of B of FIG. 3). However, PKH26-labeled UCB-MSCs had a tropism for a conditioned medium that did not contain U-87 MG cells but U-87 MG cells had been cultured therein (see D of FIG. 4). Such results show that the conditioned medium contained soluble factors that function to attract UCB-MSCs toward U-87 MG cells.

Example 5 Comparison of Tropism of BM-MSCs for U-87 MG and Tropism of UCB-MSCs for U-87 MG

A tropism of BM-MSCs for U-87 MG was compared to a tropism of UCB-MSCs for U-87 MG, using a transwell chamber. U-87 MG cancer cells or medium were placed in a lower compartment, and BM-MSCs and UCB-MSCs each were placed in an upper compartment. In all cases, the culturing was performed for two days. As a result, UCB-MSCs were found to have a stronger tropism for U-87 MG than BM-MSCs (FIG. 5).

Example 6 Comparison of Migrations of MSC

UCB-MSCs donated from four donors in the upper compartment and each of A549 that is lung cancer cell, HeLa that is cervical cancer cell, and U-87 MG that is brain cancer-glioma cell in the lower compartment were co-cultured in a transwell chamber. Then, chemotactic indices of UCB-MSCs in each case were compared (FIG. 6).

A549, HeLa, and U-87 MG cells were purchased from American type culture collection (ATCC). Each of A549 and U87 MG cells was cultured in 10-20% bovine serum-containing RPMI1640, and HeLa was cultured in DMEM. In each case, the chemotactic index was calculated by dividing the number of UCB-MSCs migrated toward U87 MG by the number of UCB-MSCs migrated in the control experiment. A tropism of UCB-MSCs for those cancer cells was analyzed. As a result, it was found that UCB-MSCs had the strongest tropism for U-87 MG that is a brain tumor cell line.

Example 7 Cytokine Array

MSCs and each of three kinds of human cells, including U-87 MG tumor cell, were co-cultured, and the cultured medium was collected. The cytokine profile from the cultured medium was examined by using a cytokine antibody array.

A film to which antibodies of various cytokine were attached was taken from a kit for a cytokine array purchased from R&D System Co. and was reacted with a blocking solution for one hour. Separately, amounts of the media prepared by co-culturing UCB-MSCs and each of three kinds of human cells, including U-87 MG tumor cell were adjusted to 1.5 mL or less, and each medium was mixed with the mixed antibodies of cyokines contained in the kit and an antigen-antibody reaction was induced for one hour. The medium in which the supplied cytokine antibodies were combined with secreted cytokines was reacted with the film that was subjected to the blocking for 4° C. for 12 hours. After the reaction, the film was placed in a washing solution and washed, and then washed with tertiary distilled water. Then the film was dried at room temperature. After repeating the washing and drying process two or three times, the film was reacted in a solution containing streptavidin-HRP for 30 minutes. Then the film was washed with a washing solution three times, reacted with a chromatic reagent, and then exposed to an X-ray film in the dark room.

U-87 MG inducing strong tropism of UCB-MSCs secreted growth-related oncogene (GRO-alpha), IL-8, MCP-1, G-CSF, GM-CSF, IL-6, IL-1β, a migration inhibitory factor (MIF), and Serpin E1. Specifically the amounts of GRO-alpha and IL-8 were higher than those of MCP-1, G-CSF, GM-CSF, IL-6, IL-1β, a MIF, and Serpin E1. FIG. 7 shows results obtained by analyzing cell lysates and cell culture supernatants through a cytokine array. Array results and information about changed spots compared to the control group are shown in FIG. 1. In Table 1, cytokines in parentheses are cytokines that were derived by the co-culturing with tumor cells. It is highly likely that these cytokines may induce a tropism of UCB-MSCs.

TABLE 1 Cell Lysate Supernatants NC37 MIF+++ MIF+++ sICAM-1++ Serpin E1+++ MIP-1a++ MIP-1a++ IL-16++ MIP-1b++ IL-6+ IL-8+ LS174-T MIF+++ MIF+++ IL-1ra++ Serpin E1+++ GROa+ IL-6+ IL-8+ U87 sICAM-1+++ (GROa+++) IL-6+++ IL-6+++ MIF+++ (IL-8+++) Serpin E1+++ Serpin E1+++ IL-1ra++ (G-CSF++) IL-8++ MIF++ G-CSF++ (MCP-1+) IL-1a+ IL-1b+

Conditioned media collected from UCB-MSCs cultures only, U-87 MG cell cultures only, and the co-culture of both cells were prepared. Each conditioned medium was incubated on an array membrane, and then visualized by an ECL reagent. Then the visualized conditioned media were compared to each other (see FIG. 8). FIG. 8A shows cytokine antibody array analysis results from the medium prepared by culturing UCB-MSCs only and a control medium. FIG. 8B shows cytokine antibody array analysis results from the medium prepared by culturing the U-87 MG only, and the medium prepared by co-culturing UCB-MSCs and U-87 MG.

FIG. 8C shows results identified by isolating mRNA from UCB-MSCs cultured with and without U-87 MG (left) or from U-87 MG cultured with and without UCB-MSCs (right). RT-PCR was performed with IL-8 specific primers and GAPDH was used as a control. When the level of IL-8 mRNA was measured by RT-PCR, it was found that U-87 MG expresses IL-8 in both cases which U-87 MG cultured with and without UCB-MSCs.

Example 8 Effect of Cytokine with Respect to UCB-MSCs Migration

The effect of IL-8, GRO-α, MCP-1 (RND Systems, MN, USA) with respect to migration of UCB-MSCs was measured using transwell migration assay. PHK-26-labelled UCB-MSCs were placed in the upper compartment and no cells were placed in the lower compartment. UCB-MSCs were cultured in an IL-8 free medium or in a medium containing different concentrations of recombinant humane IL-8 for 24 hours. As a result, it can be seen that UCB-MSCs migrated more when treated with IL-8 than when they were not treated with IL-8 (FIG. 9A).

IL-8 receptor on UCB-MSCs can be effectively blocked by anti-human CXC chemokine receptor 1 (CXCR1) antibodies. After pre-incubation of UCB-MSCs with anti-CXCR1 antibodies, recombinant IL-8 was again applied to UCB-MSCs. IL-8 mediated migration of UCB-MSCs was reduced, in a dose-dependant manner, by anti-CXCR1 treatment (FIG. 9B). Anti-CXCR2 treatment also showed the same effect.

Similarly, GRO-α treatment also enhanced UCB-MSCs migration when compared to untreated cells (FIG. 9C). GRO-α also belongs to the CC subfamily and can interact with the CXCR2 receptor [see Wuyts A. et al. Eur J Biochem 255, 67-73 (1998)].

In contrast, significant differences were not found in UCB-MSCs migration in cultures treated with MCP-1 (FIG. 9 D). These data strongly indicate that IL-8 and GRO-α participate in migration of UCB-MSCs towards U-87 MG cells.

Example 9 UCB-MSCs Migrates Toward A549 Cell Overexpressing IL-8

The relationship between the concentration of IL-8 secreted from several cancer cells and UCB-MSCs migration toward each cancer cell was identified. FIG. 10A shows ELISA results indicating concentrations of IL-8 secreted in media in which U87 MG (brain tumor), KATOIII (gastric cancer), A549 (lung cancer), and PLC/PRF5 (liver cancer) cells were cultured. In this regard, the concentration of IL-8 was measured per 1×10⁵ cells. Among the cancer cell lines assayed, U-87 MG showed the highest IL-8 production. This data suggested that UCB-MSCs had a strong migration attraction toward IL-8 producing cells. In addition, other human brain to tumor cells, that is, LN18, U138, and U251 cells, also showed the similar concentration level of IL-8 as that of U-87 MG (see FIG. 10B). Therefore, it can be seen that UCB-MSCs has a tropism for IL-8 secreted by brain tumor cells.

In order to know whether addition of IL-8 to cells expressing a lower level of IL-8 induces the migration of UCB-MSCs, IL-8 was overexpressed in A549 that is a human lung cancer cell. FIG. 10C shows migration results of UCB-MSCs after IL-8 gene was introduced to A549 cells that secrete a low level of IL-8 by using a lipofectamine reagent and then IL-8 was overexpressed. Referring to FIG. 10C, more UCB-MSCs migrated in A549 cells having overexpressed IL-8 than in A549 cells. Accordingly, it can be seen that IL-8 could be a strong inducer of UCB-MSCs migration. FIG. 10D shows the concentration of IL-8 secreted into a medium in a condition of C measured by ELISA.

Example 10 Comparison of Reaction of BM-MSCs and UCB-MSCs with Respect to IL-8

Since it is known that BM-MSCs migrate toward U-87 MG cells in vitro and in vivo, migration characteristics of BM-MSCs and UCB-MSCs with respect to U-87 MG cells were compared to those with respect to IL-8 (FIG. 11). A of FIG. 11 shows tropism characteristics of BM-MSCs and UCB-MSCs migrated toward the lower compartment B, that is, toward U87 MG. B of FIG. 11 shows tropism characteristics of BM-MSCs and UCB-MSCs migrated toward the lower compartment B when they are treated with IL-8 for 14 hours. Referring to FIG. 11, more UCB-MSCs migrated than BM-MSCs. Therefore, it can be seen that UCB-MSCs strongly corresponded to IL-8 and migrated more, but BM-MSCs relatively weakly corresponded to IL-8.

Example 11 Expression levels of the IL-8 receptor CXCR1 and CXCR2 in UCB-MSCs

Expression levels of CXCR1 and CXCR2 which are IL-8 receptors in UCB-MSCs and BM-MSCs were compared by measuring mRNA and protein in each of CXCR1 and CXCR2. FIG. 12 A shows results of RT-PCR which was performed with CXCR1 and CXCR2 primers after mRNA was isolated in each of CXCR1 and CXCR2. GAPDH was included into each sample to assess the quantity of the isolated RNA. FIG. 12 B shows results of expression levels of CXCR1 and CXCR2 obtained by measuring each mRNA band intensity of gel obtained from FIG. 12A using a densitometer (* and **, p<0.001; n=4). As a result of RT-PCR analysis for all the RNA isolated from UCB-MSCs and BM-MSCs, the band density of the PCR product of CXCR1 and CXCR2 was higher in UCB-MSCs than in BM-MSCs. FIG. 12 C shows analysis results obtained by immunostaining UCB-MSCs and BM-MSCs with anti-CXCR1 and CXCR2 antibodies to identify expression levels of CXCR1 and CXCR2 (×400). Referring to C of FIG. 12, UCB-MSCs and BM-MSCs showed high expression levels of CXCR1 and CXCR2. Since IL-8 has high affinity to CXCR1 and CXCR2, increased UCB-MSCs migration toward U-87 MG may be due to up-regulated expression of CXCR1 and CXCR2. FIG. 12 D shows analysis results obtained by immunostaining UCB-MSCs and BM-MSCs with a secondary antibody only without anti-CXCR1 and CXCR2 antibodies to identify antigen specificity of the anti-CXCR1 and CXCR2 antibodies.

Example 12 Introduction of Gene into Umbilical Cord Blood Mesenchymal Stem Cell

As an example of an experiment in which a gene is introduced into UCB-MSCs, a green fluorescent protein (GFP) was overexpressed using an electroporation method with a human MSC neucleofector produced by amaxa biosystem Co. and an electroporation method. 4×10⁵ cells of UCB-MSCs were cultured for two days and then placed in a mixture of 5 mg of a GFP encoding gene and 100 ml of a human MSC nucelofector for 15 minutes and the gene was introduced in an electroporator. The resultant UCB-MSCs was moved to a plate and after 24 hours, expression levels of GFP were identified with a fluorescent microscope. The GFP could be identified in a cytoplasm of each MSC (see FIG. 13).

To test a tropism of UCB-MSCs to which the GFP encoding gene is introduced, each of a GFP encoding gene and an empty gene was overexpressed in UCB-MSCs and then, a tropism of the resultant UCB-MSCs for U-87 MG was identified. After the gene was introduced as described above, UCB-MSCs expressing GFP were placed in an upper compartment of a transwell chamber and U-87 MG was placed in a lower compartment of the transwell chamber, and then UCB-MSCs expressing GFP and U-87 MG were co-cultured for 24 hours. Among cells migrated toward the lower compartment, GFP positive cells were identified. As a result, it can be seen that UCB-MSCs overexpressing GFP due to introduction of a GFP gene had a strong tropism for U87 MG (FIG. 14).

DESCRIPTION OF THE DRAWINGS

FIG. 1 is a view illustrating a process of collecting mesenchymal stem cells (MSCs);

FIG. 2 is a schematic view of a transwell chamber that is used to co-culture umbilical cord blood derived mesenchymal stem cells (UCB-MSCs) and various cell lines according to the present invention;

FIG. 3 is a graph of the number of UCB-MSCs migrated toward a lower compartment of a transwell chamber when PKH-labeled UCB-MSCs placed in an upper compartment of the transwell chamber and each of U-87 MG, LS174-T, NC-37, and NIH3T3 cells placed in the lower compartment of the transwell chamber are co-cultured, wherein: in (A), a left bar indicates a case in which the cell number of cell lines in the lower compartment in the transwell chamber is 1×10⁵ cells and a right bar indicates a case in which the cell number of cell lines in the lower compartment in the transwell chamber is 5×10⁵ cells, and in both cases, the number of UCB-MSCs is 1×10⁵ cells and in (B), a left fluorescent microscopic image shows PKH26-labeled UCB-MSCs migrated toward the lower compartment of the transwell chamber when a human cell line-free medium only is used (control), and a right fluorescent microscopic image shows PKH26-labeled UCB-MSCs migrated toward the lower compartment of the transwell chamber when-UCB-MSCs are co-cultured with U-87 MG cells;

FIG. 4 is a graph of the number of UCB-MSCs migrated toward the lower compartment of the transwell chamber when PKH-labeled UCB-MSCs placed in the upper compartment of the transwell chamber and each of U-87 MG, KATO III, A549, PLC/PRF5, LN18, U138, and U251 cells placed in the lower compartment of the transwell chamber are co-cultured (A and C), wherein (B) is an fluorescent microscopic image of PKH26-labeled UCB-MSCs migrated toward the lower compartment, and (D) is a graph of the number of UCB-MSCs migrated when UCB-MSCs are co-cultured with U-87 MG cells, or with U87 MG cells-free cultured-conditioned media which is prepared by culturing U87 MG cells in media and then removing U87 MG cells from the media;

FIG. 5 is a graph for comparing tropisms of BM-MSCs and UCB-MSCs for U-87 MG cells, wherein each of PKH-labeled UCB-MSCs and PKH-labeled BM-MSCs placed in the upper compartment in the transwell chamber and U-87 MG cells placed in the lower compartment in the transwell chamber are co-cultured and the number of PKH-labeled UCB-MSCs migrated toward the lower compartment is compared with the number of PKH-labeled BM-MSCs, wherein a left bar indicates a case in which U-87 MG cells do not exist and a right bar indicates a case in which U-87 MG cells exist (the number of U-87 MG cells is 5×10⁵, and in both cases, the number of MSCs is 1×10⁵;

FIG. 6 is a graph of chemotactic indices of UCB-MSCs when UCB-MSCs are co-cultured with cancer cell lines (A549, HeLa, and U-87 MG cells);

FIG. 7 shows results obtained by analyzing cell lysates and cell culture supernatants through a cytokine array after each of NC37, LS174-T, and U-87 MG cells is co-cultured with UCB-MSCs;

FIG. 8 shows analysis results obtained by collecting conditioned media in which UCB-MSCs were cultured alone, U-87 MG cells were cultured alone, and both of UCB-MSCs to and U-87 MG cells were co-cultured, incubating the conditioned media on an array membrane, and then visualizing the incubated results with ECL reagents, wherein (A) shows cytokine antibody array analysis results from the conditioned media with UCB-MSCs and medium control, (B) shows analysis results when the conditioned media in which U-87 MG only is cultured is used and when the media in which a UCB-MSCs and U-87 MG are co-cultured is used, and (C) shows mRNA isolation results from UCB-MSCs (left) cultured with or without U-87 MG cells or UCB-MSCs, and from U-87 MG cells cultured with and without UCB-MSCs, wherein RP-PCT is performed with IL-8 specific primers and GAPDH is used as a control group;

FIG. 9 is a graph for identifying the effect of IL-8 and GRO-α, among the cytokines analyzed with reference to FIG. 8, on MSC migration, wherein (A) is a graph of cell migration toward the lower compartment when MSCs are treated with a recombinant IL-8 protein for 0, 1, 10, and 100 ng for 24 hours, (B) is a graph of cell migration toward the lower compartment when UCB-MSCs are pre-treated with 0.02, 0.2, and 2 μg of a CXC chemokine receptor 1 (CXCR1) antibody that is known as a receptor of IL-8 in cells and then treated with 50 ng of IL-8 to promote the MSC migration. (*, p=0.007; **, p<0.001), (C) is a graph of cell migration toward the lower compartment when UCB-MSCs are treated with GRO-α (*, p<0.005), and (D) is a graph of cell migration when MSCs are treated with Monocyte chemoattractant protein-1 (MCP-1);

FIG. 10 consists of (A), (B), (C), and (D), wherein (A) and (B) are graphs of the amount of IL-8 secreted in the cultured media with U-87 MG, KATO Ill, A549, PLC/PRF5, LN18, U138, and U251 cells, measured by ELISA, (C) is a graph of cell migration when IL-8 gene is introduced to A549 cell secreting a low level of IL-8 and overexpressed, and (D) is a graph of the amount of IL-8 secreted in the media in the condition of (C), measured by ELISA;

FIG. 11 are graphs for comparing tropisms of UCB-MSCs and BM-MSCs for U-87 MG cells, wherein (A) is a graph for comparing tropism of UCB-MSCs and BM-MSCs moved toward the lower compartment, with respect to U-87 MG cells, and (B) is a graph for comparing tropism of UCB-MSCs and BM-MSCs when UCB-MSCs and BM-MSCs are treated with IL-8 for 14 hours;

FIG. 12 show analysis results for comparing expression levels of CXC chemokine receptor 1 and CXC chemokine receptor 2 (CXCR1 and CXCR2), which are known as IL-8 receptors, in UCB-MSCs and BM-MSCs, by measuring mRNA and protein, wherein (A) shows analysis results when mRNA is separated from each of UCB-MSCs and BM-MSCs and RT-PCR was performed with CXCR1 and CXCR2 primers in UCB-MSCs and BM-MSCs, wherein the separated RNA was quantified with reference to GAPDH reacted with each sample, (B) is a graph of expression levels of CXCR1 and CXCR2 by measuring the band intensity of mRNA of each gel obtained from (A) with a densitometer (* and **, p<0.001; n=4), (C) shows analysis results of protein expression levels of CXCR1 and CXCR2 in UCB-MSCs and BM-MSCs by performing a immunostaining process and anti-CXCR1 and CXCR2 antibodies (×400), and (D) shows analysis results obtained by immunostaining UCB-MSCs and BM-MSCs with a secondary antibody only instead of anti-CXCR1 and CXCR2 antibodies to identify antigen specificity of the anti-CXCR1 and CXCR2 antibodies;

FIG. 13 is a fluorescent microscopic image of UCB-MSCs to which a gene coding green fluorescent protein (GFP) is introduced and overexpressed;

FIG. 14 shows results of an experiment in which each of the gene coding GFP and an empty gene is overexpressed in UCB-MSCs. Said UCB-MSCs are placed in a upper compartment in a transwell and U-87 MG cells are placed in a lower compartment in the transwell and cocultured for 24 hours, and then UCB-MSCs migrated toward the lower compartment are identified; and

FIG. 15 shows primer sequences used in Examples of the present invention. 

1. A method of preventing or treating a tumor comprising administering to a subject an effective dose of a composition comprising mesenchymal stem cells derived from umbilical cord blood (UCB-MSC).
 2. The method of claim 1, wherein a cell of the tumor expresses at least one gene selected from a group of a gene encoding IL-8 and a gene encoding GRO-α.
 3. The method of claim 1, wherein the tumor is selected from the group consisting of a brain tumor, a liver hepatoma, a breast cancer, a colon cancer and a B-cell neoplasm.
 4. The method of claim 1, wherein an anti-tumor agent gene is introduced into the UCB-MSC.
 5. The method of claim 4, wherein the anti-tumor agent gene is selected from the group consisting of a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory factor gene and an angiogenesis inhibitor gene.
 6. The method of claim 5, wherein the tumor suppressor gene is selected from the group consisting of a gene encoding phosphatase and tensin homolog (PTEN), a gene encoding Maspin, a gene encoding RUNX3, a gene encoding Caveolin-1, a gene encoding nm23, a gene encoding Rb protein, a gene encoding Brush-1, a gene encoding inhibitor of tumor growth (ING-4), a gene encoding survivin, a gene encoding X chromosome linked inhibitor apoptosis protein (XIAP), a gene encoding neural apoptosis inhibitory protein (NAIP) and genes encoding proteins related to regulation of said genes.
 7. The method of claim 5, wherein the apoptosis inducing factor gene is selected from the group consisting of a gene encoding cytokine, a gene encoding interleukin, a gene encoding a tumor necrosis factor (TNF), a gene encoding interferon (INF-α, INF-β, INF-γ), a gene encoding a colony stimulating factor (CSFs), a gene encoding p53, a gene encoding Apaf-1, a gene encoding TRAIL, a gene encoding Caspase, a gene encoding Bax, a gene encoding Bad, a gene encoding FADD, a gene encoding JNK, a gene encoding p38 kinase and genes encoding proteins related to regulation of said genes.
 8. The method of claim 7, wherein the cell cycle regulatory factor gene is selected from the group consisting of a gene encoding cdc2, a gene encoding Cyclin (Cyclin A, Cyclin D, Cyclin E), a gene encoding cdc25C, a gene encoding WAF, a gene encoding INK4, a gene encoding CDK (CDK1, CDK2, CDK4, CDK6), a gene encoding Rb protein, a gene encoding E2F, an antisense or siRNA thereof and genes encoding proteins related to the regulation of said genes.
 9. The method of claim 5, wherein the angiogenesis inhibitor gene is selected from the group consisting of a gene encoding thrombospondin-1, a gene encoding endostatin, a gene encoding tumstatin, a gene encoding canstatin, a gene encoding vastatin, a gene encoding restin, a gene encoding a vascular endothelial growth factor inhibitor, a gene encoding maspin, a gene encoding angiopoietins, a gene encoding 16-kd prolactin fragment and a gene encoding endorepellin.
 10. The method of claim 1, wherein a prodrug converting enzyme gene is introduced to the UCB-MSC.
 11. The method of claim 10, wherein the method further comprises administering a prodrug of an anticancer drug.
 12. The method of claim 10, wherein the prodrug converting enzyme gene is selected from cytosine deaminase gene and CYP2B 1 gene.
 13. The method of claim 1, wherein an antisense or siRNA of a gene related to brain tumor is introduced to the UCB-MSC.
 14. The method of claim 13, wherein the gene related to brain tumor is selected from the group consisting of a gene encoding a Ras family protein, a gene encoding c-myc, a gene encoding abl, a gene encoding erbB-1, a gene encoding EGFR, a gene encoding Bax, a gene encoding Apaf-1 interacting protein (APIP), a gene encoding Wnt-1-induced secreted protein 1 (WISP-1), a gene encoding Wnt, a gene encoding Raf-1, a gene encoding Src, a gene encoding Akt, a gene encoding Erk-1, 2 and a gene encoding BcL-2.
 15. The method of claim 1, wherein an oncolytic virus is introduced to the UCB-MSC.
 16. The method of claim 15, wherein the oncolytic virus is selected from Herpes simplex virus and Reovirus type
 3. 17. The method of claim 3, wherein the brain tumor is selected from the group consisting of astrocytoma, pilocytic astrocytoma, low-grade astrocytoma, anaplastic astrocytoma, glioblastoma multiforme, brain stem cell glioma, ependymoma, subependymoma, ganglioneuroma, mixed glioma, oligodendroglioma, optic nerve glioma, acoustic neuroma, chordoma, CNS lymphoma, craniopharyngioma, hemangioblastoma, medulloblastoma, meningioma, pineal tumors, pituitary tumors, primitive neuroectodermal tumors, rhabdoid tumors, schwannoma, cysts, neurofibromatosis, pseudotumor cerebri and tuberous sclerosis.
 18. The method of claim 1, further comprises enhancing the expression level of at least one gene selected from the group consisting of a gene encoding IL-8 receptor and a gene encoding GRO-α receptor at the USC-MSC.
 19. The method of claim 18, wherein the IL-8 receptor is selected from a group consisting of CXCR1 and CXCR2.
 20. The method of claim 18, wherein the GRO-α receptor CXCR2.
 21. The method of claim 18, wherein the enhancement of the expression is achieved by at least one selected from the group consisting of activating the endogenous gene and introducing an exogenous gene.
 22. A kit for identifying the location and the size of a brain tumor, comprising UCB-MSC, said UCB-MSC being labeled with a detectable marker.
 23. The kit of claim 22, wherein the detectable marker is selected from luciferase-containing enzyme-based fluorescent detector and Tat peptide-derivatized magnetic nanoparticles.
 24. A method of identifying the location and the size of a brain tumor of a subject, wherein the method comprises: (a) administering to the subject UCB-MSC; (b) identifying the location and the size of the distribution of the administered UCB-MSC.
 25. The method of claim 24, wherein the UCB-MSC are labeled with a detectable marker.
 26. The method of claim 24, wherein the detectable marker is selected from luciferase-containing enzyme-based fluorescent detector and Tat peptide-derivatized magnetic nanoparticles.
 27. A method of monitoring a progression of a tumor treatment in a subject who is received the brain tumor treatment, wherein the method comprises: (a) first administering to the subject UCB-MSC; (b) identifying the location and the size of the distribution of the first administered UCB-MSC in the subject; (c) second administering to the subject UCB-MSC; (d) identifying the location and the size of the distribution of the second administered UCB-MSC in the subject; (e) comparing the location and the size of the distribution identified by (b) and (d), wherein the subject receives a treatment of the tumor during the period starting from the first administration of the UCB-MSC to the second administration of the UCB-MSC.
 28. The method of claim 27, wherein the UCB-MSC are labeled with a detectable marker.
 29. The method of claim 28, wherein the detectable marker is selected from luciferase-containing enzyme-based fluorescent detector and Tat peptide-derivatized magnetic nanoparticles.
 30. A method for delivering a therapeutic gene to a site of a subject, the site comprising cells expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cells, wherein the method comprises the step of administering to the subject an effective dose of the UCB-MSC.
 31. The method of claim 30, wherein the therapeutic gene is introduced into the UCB-MSC.
 32. The method of claim 30, wherein the therapeutic gene is selected from the group consisting of a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory gene and an angiogenesis inhibitor gene.
 33. The method of claim 32, wherein the tumor suppressor gene is selected from the group consisting of a gene encoding phosphatase and tensin homolog (PTEN), a gene encoding Maspin, a gene encoding RUNX3, a gene encoding Caveolin-1, a gene encoding nm23, a gene encoding Rb protein, a gene encoding Brush-1, a gene encoding inhibitor of tumor growth (ING-4), a gene encoding survivin, a gene encoding X chromosome linked inhibitor apoptosis protein (XIAP), a gene encoding neural apoptosis inhibitory protein (NAIP), and genes encoding proteins related to the regulation of said genes.
 34. The method of claim 32, wherein the apoptosis-inducing factor gene is selected from the group consisting of a gene encoding cytokine, a gene encoding interleukin, a gene encoding a tumor necrosis factor (TNF), a gene encoding interferon (INF-α, INF-β, INF-γ), a gene encoding a colony stimulating factor (CSFs), a gene encoding p53, a gene encoding Apaf-1, a gene encoding TRAIL, a gene encoding Caspase, a gene encoding Bax, a gene encoding Bad, a gene encoding FADD, a gene encoding JNK, a gene encoding p38 kinase, and genes encoding proteins related to the regulation of said genes.
 35. The method of claim 32, wherein the cell cycle regulatory factor gene is selected from the group consisting of a gene encoding cdc2, a gene encoding Cyclin Cyclin A, Cyclin D, Cyclin E), a gene encoding cdc25C, a gene encoding WAF, a gene encoding INK4, a gene encoding CDK (CDK1, CDK2, CDK4, CDK6), a gene encoding Rb protein, a gene encoding E2F, an antisense or SiRNA thereof, and genes encoding proteins related to the regulation of said genes.
 36. The method of claim 32, wherein the angiogenesis inhibitor gene is selected from the group consisting of a gene encoding thrombospondin-1, a gene encoding endostatin, a gene encoding tumstatin, a gene encoding canstatin, a gene encoding vastatin, a gene encoding restin, a gene encoding a vascular endothelial growth factor inhibitor, a gene encoding maspin, a gene encoding angiopoietins, a gene encoding 16-kd prolactin fragment and a gene encoding endorepellin.
 37. The method of claim 30, wherein a prodrug converting enzyme gene is introduced to the UCB-MSC.
 38. The method of claim 30, wherein the method further comprises administering a prodrug of an anticancer drug.
 39. The method of claim 37, wherein the prodrug converting enzyme gene is selected from the group consisting of cytosine deaminase gene and a CYP2B 1 gene.
 40. The method of claim 30, wherein an antisense or siRNA of a gene related to tumor is introduced to the UCB-MSC.
 41. The method of claim 40, wherein the gene related to tumor is selected from the group consisting of a gene encoding Ras family protein, a gene encoding c-myc, a gene encoding abl, a gene encoding erbB-1, a gene encoding EGF-R, a gene encoding Bax, a gene encoding an Apaf-1 interacting protein (APIP), a gene encoding Wnt-1-induced secreted protein 1 (WISP-1), a gene encoding Wnt, a gene encoding Raf-1, a gene encoding Src, a gene encoding Akt, a gene encoding Erk-1,2 and a gene encoding BcL-2.
 42. The method of claim 30, wherein an oncolytic virus is introduced to the UCB-MSC.
 43. The method of claim 42, wherein the oncolytic virus is selected from the group consisting of Herpes simplex virus and Reovirus type
 3. 44. The method of claim 30, wherein the cell expressing at least one selected from the group consisting of IL-8 and GRO-α is selected from the group consisting of a brain tumor cell, a hepatoma cell, a breast cancer cell, a lung cell with an acute respiratory distress syndrome, a colon cancer cell and a B-cell neoplasm cell.
 45. The method of claim 44, wherein the B-cell neoplasm cell is selected from the group consisting of a common B acute lymphoblastic leukemia cell, a precursor B acute lymphoblastic leukemia cell, a B-cell chronic lymphocytic leukemia cell, a mantle cell lymphoma cell, a Burkitt's lymphoma cell and a Follicular lymphoma cell.
 46. A kit for identifying the location and the size of a site of a subject, the site comprising cells expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cells, wherein the kit comprises UCB-MSC, the UCB-MSC are labeled with a detectable marker.
 47. The kit of claim 46, wherein the detectable marker is selected from luciferase-containing enzyme-based fluorescent detector and Tat peptide-derivatized magnetic nanoparticles.
 48. The kit of claim 46, wherein the cell expressing at least one selected from the group consisting of IL-8 and GRO-α is selected from the group consisting of a brain tumor cell, a hepatoma cell, a breast cancer cell, a lung cell with an acute respiratory distress syndrome, a colon cancer cell and a B-cell neoplasm cell.
 49. The kit of claim 48, wherein the B-cell neoplasm cell is selected from the group consisting of a common B acute lymphoblastic leukemia cell, a precursor B acute lymphoblastic leukemia cell, a B-cell chronic lymphocytic leukemia cell, a mantle cell lymphoma cell, a Burkitt's lymphoma cell and a Follicular lymphoma cell.
 50. A method of identifying the location and the size of a site of a subject, the site comprising cells expressing at least one selected from the group consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC toward the cells, wherein the method comprises: (a) administering to the subject UCB-MSC; (b) identifying the location and the size of the distribution of the administered UCB-MSC.
 51. The method of claim 50, wherein the UCB-MSC are labeled with a detectable marker.
 52. The method of claim 51, wherein the detectable marker is selected from luciferase-containing enzyme-based fluorescent detector and Tat peptide-derivatized magnetic nanoparticles.
 53. The method of claim 50, wherein the cell expressing at least one selected from the group consisting of IL-8 and GRO-α is selected from the group consisting of a brain tumor cell, a hepatoma cell, a breast cancer cell, a lung cell with an acute respiratory distress syndrome, a colon cancer cell and a B-cell neoplasm cell.
 54. The method of claim 53, wherein the B-cell neoplasm cell is selected from the group consisting of a common B acute lymphoblastic leukemia cell, a precursor B acute lymphoblastic leukemia cell, a B-cell chronic lymphocytic leukemia cell, a mantle cell lymphoma cell, a Burkitt's lymphoma cell and a Follicular lymphoma cell.
 55. A method of monitoring treatment progression of a disease occurred in a site of a subject, the site comprising cells expressing at least one selected from groups consisting of IL-8 and GRO-α and inducing tropism of UCB-MSC, wherein the method comprises: (a) first administering to the subject UCB-MSC; (b) identifying the location and the size of the distribution of the first administered UCB-MSC in the subject; (a) second administering to the subject UCB-MSC; (b) identifying the location and the size of the distribution of the second administered UCB-MSC in the subject; and (c) comparing the location and the size of the distribution identified by (b) and (d), wherein the subject receives a treatment of the tumor during the period starting from the first administration of the UCB-MSC to the second administration of the UCB-MSC.
 56. The method of claim 55, wherein the UCB-MSC are labelled with a detectable marker.
 57. The method of claim 56, wherein the detectable marker is selected from luciferase-containing enzyme-based fluorescent detector and Tat peptide-derivatized magnetic nanoparticles.
 58. The method of claim 55, wherein the cell expressing at least one selected from the group consisting of IL-8 and GRO-α is selected from the group consisting of a brain tumor cell, a hepatoma cell, a breast cancer cell, a lung cell with an acute respiratory distress syndrome, a colon cancer cell and a B-cell neoplasm cell.
 59. The method of claim 56, wherein the B-cell neoplasm cell is selected from the group consisting of a common B acute lymphoblastic leukemia cell, a precursor B acute lymphoblastic leukemia cell, a B-cell chronic lymphocytic leukemia cell, a mantle cell lymphoma cell, a Burkitt's lymphoma cell and a Follicular lymphoma cell.
 60. A method of delivering an anti-tumor agent to a site of a tumor in a subject, which comprises administering mesenchymal stem cells together with the anti-tumor agent to the site, wherein the mesenchymal stem cells (MSCs) are umbilical cord blood-derived MSCs (“UCB-MSC”).
 61. The method according to claim 60, wherein the MSCs are used in an amount of 1×10⁴-1×10⁷ cells/kg body weight.
 62. The method according to claim 60, wherein the anti-tumor agent is selected from the group consisting of a tumor suppressor gene, an apoptosis-inducing factor gene, a cell cycle regulatory factor gene and an angiogenesis inhibitor gene.
 63. The method according to claim 60, wherein the anti-tumor agent is admixed with the UCB-MSCs.
 64. The method according to claim 60, wherein the anti-tumor agent is carried within the UCB-MSCs.
 65. The method according to claim 60, wherein the tumor is a brain tumor.
 66. The method according to claim 62, wherein the tumor suppressor gene is selected from the group consisting of phosphatase and tensin homolog gene (PTEN), Maspin gene, RUNX3 gene, Caveolin-1 gene, nm23 gene, Rb protein gene, Brush-1 gene, a gene encoding an inhibitor of tumor growth (ING-4), surviving gene, X chromosome linked inhibitor apoptosis protein (XIAP) gene, neural apoptosis inhibitory protein (NAIP) gene and genes encoding a protein related to regulating said genes.
 67. The method according to claim 62, wherein the apoptosis inducing factor gene is selected from the group consisting of a gene encoding cytokine, a gene encoding interleukin, a gene encoding a tumor necrosis factor (TNF), a gene encoding interferon (INF-α, INF-β, INF-γ), a gene encoding a colony stimulating factor (CSFs), a gene encoding p53, a gene encoding Apaf-1, a gene encoding TRAIL, a gene encoding Caspase, a gene encoding Bax, a gene encoding Bad, a gene encoding FADD, a gene encoding JNK, a gene encoding p38 kinase and genes encoding proteins related to regulating said genes.
 68. The method according to claim 62, wherein the cell cycle regulatory factor gene is selected from the group consisting of a gene encoding cdc2, a gene encoding Cyclin (Cyclin A, Cyclin D, Cyclin E), a gene encoding cdc25C, a gene encoding WAF, a gene encoding INK4, a gene encoding CDK (CDK1, CDK2, CDK4, CDK6), a gene encoding Rb protein, a gene encoding E2F, an antisense or siRNA thereof and genes encoding proteins related to regulating said genes.
 69. The method according to claim 62, wherein the angiogenesis inhibitor gene is selected from the group consisting of a gene encoding thrombospondin-1, a gene encoding endostatin, a gene encoding tumstatin, a gene encoding canstatin, a gene encoding vastatin, a gene encoding restin, a gene encoding a vascular endothelial growth factor inhibitor, a gene encoding maspin, a gene encoding angiopoietins, a gene encoding 16-kd prolactin fragment and a gene encoding endorepellin.
 70. The method according to claim 60, wherein the anti-tumor agent is a prodrug converting enzyme gene.
 71. The method according to claim 60, wherein the anti-tumor agent is an antisense or siRNA of a gene related to a brain tumor.
 72. The method according to claim 71, wherein the gene related to brain tumor is selected from the group consisting of a gene encoding Ras family, a gene encoding c-myc, a gene encoding abl, a gene encoding erbB-1, a gene encoding EGF-R, a gene encoding Bax, a gene encoding Apaf-1 interacting protein (APIP), a gene encoding Wnt-1-induced secreted protein 1 (WISP-1), a gene encoding Wnt, a gene encoding Raf-1, a gene encoding Src, a gene encoding Akt, a gene encoding Erk-1,2 and a gene encoding BcL-2.
 73. The method according to claim 60, wherein the anti-tumor agent is an oncolytic virus.
 74. The method according to claim 73, wherein the oncolytic virus is selected from Herpes simplex virus and Reovirus type
 3. 75. The method according to claim 74, wherein the brain tumor is selected from the group consisting of astrocytoma, pilocytic astrocytoma, low-grade astrocytoma, anaplastic astrocytoma, glioblastoma multiforme, brain stem glioma, ependymoma, subependymoma, ganglioneuroma, mixed glioma, oligodendroglioma, optic nerve glioma, acoustic neuroma, chordoma, CNS lymphoma, craniopharyngioma, hemangioblastoma, medulloblastoma, meningioma, pineal tumors, pituitary tumors, primitive neuroectodermal tumors, rhabdoid tumors, schwannoma, cysts, neurofibromatosis, pseudotumor cerebri and tuberous sclerosis. 